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Multivalent poultry vaccine development 
using Protein Glycan Coupling Technology
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Alexander A. Smith2, Cosmin Chintoan‑Uta3, Abi Bremner3, Vanessa S. Terra1, Sherif Abouelhadid1, 
Mark P. Stevens3*†, Andrew J. Grant2*†, Jon Cuccui1*† and Brendan W. Wren1*† on behalf of the 
Glycoengineering of Veterinary Vaccines Consortium 
Abstract 
Background: Poultry is the world’s most popular animal‑based food and global production has tripled in the past 
20 years alone. Low‑cost vaccines that can be combined to protect poultry against multiple infections are a current 
global imperative. Glycoconjugate vaccines, which consist of an immunogenic protein covalently coupled to glycan 
antigens of the targeted pathogen, have a proven track record in human vaccinology, but have yet to be used for live‑
stock due to prohibitively high manufacturing costs. To overcome this, we use Protein Glycan Coupling Technology 
(PGCT), which enables the production of glycoconjugates in bacterial cells at considerably reduced costs, to generate 
a candidate glycan‑based live vaccine intended to simultaneously protect against Campylobacter jejuni, avian patho‑
genic Escherichia coli (APEC) and Clostridium perfringens. Campylobacter is the most common cause of food poisoning, 
whereas colibacillosis and necrotic enteritis are widespread and devastating infectious diseases in poultry.
Results: We demonstrate the functional transfer of C. jejuni protein glycosylation (pgl) locus into the genome of 
APEC χ7122 serotype O78:H9. The integration caused mild attenuation of the χ7122 strain following oral inocula‑
tion of chickens without impairing its ability to colonise the respiratory tract. We exploit the χ7122 pgl integrant as 
bacterial vectors delivering a glycoprotein decorated with the C. jejuni heptasaccharide glycan antigen. To this end we 
engineered χ7122 pgl to express glycosylated NetB toxoid from C. perfringens and tested its ability to reduce caecal 
colonisation of chickens by C. jejuni and protect against intra‑air sac challenge with the homologous APEC strain.
Conclusions: We generated a candidate glycan‑based multivalent live vaccine with the potential to induce protec‑
tion against key avian and zoonotic pathogens (C. jejuni, APEC, C. perfringens). The live vaccine failed to significantly 
reduce Campylobacter colonisation under the conditions tested but was protective against homologous APEC 
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Background
Healthily maintained livestock are essential for eco-
nomic and societal prosperity [1]. Poultry are the main 
source of meat and eggs worldwide. The world’s chicken 
flock is now estimated to be around 66 billion broil-
ers and 21 billion layers [2]. Poultry meat production 
has grown 12-fold in the past 50 years [2]. Additionally, 
poultry accounts for egg production, which globally has 
increased threefold in the last three decades with c. 87 
billion eggs estimated to be produced per annum [3]. 
However, infectious diseases remain a significant impedi-
ment to poultry welfare and productivity. Consequently, 
there is a growing demand to identify successful strate-
gies to prevent the spread of diseases within and from 
flocks, to avert significant economic losses and to miti-
gate the healthcare burden resulting from zoonoses aris-
ing from poultry products.
The most common bacterial infections encountered in 
poultry are colibacillosis, mycoplasmosis, and salmonel-
losis, caused by avian pathogenic E. coli (APEC), Myco-
plasma gallisepticum (and less frequently by Mycoplasma 
synoviae and Mycoplasma meleagridis), and Salmonella 
enterica species (mostly Salmonella enterica serovar 
Pullorum and Salmonella enterica serovar Gallinarum), 
respectively [4]. Other less common, but possibly severe 
bacterial infections include fowl cholera, necrotic enteri-
tis, botulism and tuberculosis [4]. Aside from contracting 
infections, poultry can also transmit zoonotic diseases of 
public health concern to humans, such as campylobac-
teriosis, salmonellosis, and avian influenza viruses caus-
ing gastroenteritis, diarrhoea and fever [5]. In Europe 
and the UK, for instance, bacterial species of Campylo-
bacter and Salmonella are the top two reported bacterial 
gastrointestinal pathogens in humans. These are WHO-
listed high priority pathogens given the rise of antibiotic 
resistant species, and undercooked chicken meat and 
eggs are key sources of human infection [6–8]. The dis-
eases they cause are usually self-limiting in people, but in 
severe cases they require hospitalisation, and can result 
in death, generally posing a higher threat for children 
younger than 5  years, people with weakened immune 
systems, pregnant women and the elderly [5]. Worse out-
comes, particularly in young children, are more common 
in poor settings lacking safe water, effective sanitation, 
standard hygiene, and hospital access, emphasising the 
global health concerns around zoonotic enteritis and the 
importance of the One Health approach (health for peo-
ple, animals and the environment) to tackle them [6, 9, 
10].
General recommendations to reduce the spread of 
infectious diseases are the implementation of generic 
hygiene measures, together with safe cooking and food 
handling practices to avoid consumption of raw or under-
cooked animal products [11]. Alongside these practices, 
the introduction of vaccines has been one of the most 
impactful and cost-effective public health measures to 
prevent the spread of diseases (reviewed in [12]), saving 
an estimated 2–3 million lives each year [13]. Amongst 
the different types of vaccines that exist to date, glycocon-
jugates, consisting of a glycan antigen from the surface of 
the target pathogen covalently coupled to a protein car-
rier with strong immunogenic properties, have a proven 
track record in human vaccinology for safety and efficacy 
[14]. In fact, since the introduction of licensed glycocon-
jugate vaccines against Haemophilus influenzae type b, 
Streptococcus pneumoniae, and Neisseria meningitidis 
from the 1980s, the incidence of pneumonia and menin-
gitis has dramatically decreased [12, 15]. The key element 
of their effectiveness in inducing durable B- and T-cell 
responses is the coupling of the glycan and protein moie-
ties, a crucial observation that stemmed from pioneering 
work of Avery and Goebbels in the 1920s [16]. Linking 
a carrier protein to a glycan antigen overcomes the limi-
tations of polysaccharide-only vaccines, which fail to 
induce protection in infants younger than 18  months, 
are T-cell independent antigens and fail to induce immu-
nological memory [17–19]. The traditional production 
of glycoconjugates, however, is a convoluted multi-step 
process that requires large scale cultures of pathogenic 
microorganisms as a source of the glycan antigen or 
chemical synthesis of the glycan, the separate produc-
tion of a recombinant carrier protein, and the chemical 
or enzymatic coupling of the two. The complexity of the 
production process is reflected in high costs that has so 
far hindered their use in the veterinary field.
To circumvent cost and biosafety issues, we employ 
Protein Glycan Coupling Technology (PGCT), which 
utilises modified bacterial strains to produce glycocon-
jugates recombinantly in  vivo (reviewed in [20, 21]). 
This biotechnology stemmed from the discovery of an 
N-linked protein glycosylation locus (pgl) in the bacte-
rium C. jejuni [22, 23] and its functional transfer to E. 
challenge. Nevertheless, we present a strategy towards the production of low‑cost “live‑attenuated multivalent vac‑
cine factories” with the ability to express glycoconjugates in poultry.
Keywords: Vaccine, Glycoconjugates, PGCT , Glycoengineering, Live‑attenuated, Poultry, One Health, Campylobacter 
jejuni, APEC, NetB
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coli [24]. The subsequent observations that the oligo-
saccharyltransferase (OST) of the pgl locus, PglB, has 
relaxed specificity for its glycan substrate [25] and the 
identification of a relatively short PglB acceptor sequon, 
D/EXNXS/T (where X is any amino acid except proline) 
[26], paved the way for exploiting PGCT for glycocon-
jugate production. Since then this process, also known 
as bioconjugation, has been continuously improved and 
used to produce multiple candidate glycoconjugate vac-
cines from safe laboratory-adapted strains of E. coli (for a 
comprehensive list see Table 3 in [20]). The recombinant 
expression of glycoproteins is usually achieved by trans-
forming suitable E. coli strains with plasmids encoding 
the functional components of the system: the glycan anti-
gen, a carrier protein of choice and an OST capable of 
coupling the two. Alternatively, these components can be 
chromosomally integrated to overcome the use of plas-
mids. Interestingly, PGCT has already been successfully 
employed to produce recombinant vaccine candidates for 
poultry. Work form the Szymanski group has shown that 
a diphtheria toxin fused to a C. jejuni peptide containing 
nine acceptor sequons modified with C. jejuni heptasac-
charide significantly reduced Campylobacter colonisa-
tion of the chicken gut [27]. A prior study from our group 
generated SodB and FlpA glycoconjugates where both 
protein and glycan antigen target Campylobacter species 
[28]. These candidates failed to reduce Campylobacter 
colonisation in the chosen vaccination schedule, pos-
sibly owing to lower levels of protein glycosylation than 
reported by others but are undergoing further improve-
ments to boost their immunogenicity.
PGCT is not limited to glycoengineering strains of E. 
coli, but it can be applied to other Gram-negative bac-
teria circumventing the need for heterologous glycan 
locus expression, which can be challenging. Successful 
examples in this respect include the application of PGCT 
to Shigella flexneri 2a [29], Salmonella enterica sero-
var Paratyphi [30] and Yersinia enterocolitica O9, which 
shares the same glycan structure of Brucella suis and 
Brucella abortus, while belonging to a lower biohazard 
level [31, 32].
In this study we utilise PGCT to develop a multiva-
lent live vaccine for poultry capable of expressing heter-
ologous glycoproteins in vitro and in vivo. The modified 
APEC live vaccine is exploited as a vector for the delivery 
of the Clostridium perfringens NetB toxoid coupled to 
the Campylobacter jejuni heptasaccharide glycan. Thus, 
the candidate trivalent vaccine has the potential to pro-
tect poultry from colibacillosis and necrotic enteritis 
caused by APEC and C. perfringens, respectively, and to 
reduce Campylobacter colonisation of the chicken gut 
to prevent zoonotic gastroenteritis. As a bacterial vector 
we chose a widely studied APEC strain (χ7122) from a 
serotype (O78:H9) and sequence type (ST23) that is com-
monly associated with colibacillosis in poultry worldwide 
[33]. We transferred the pgl locus from C. jejuni, which 
encodes a conserved heptasaccharide glycan expressed 
by all thermophilic Campylobacter species (including C. 
jejuni and C. coli, which are the most reported causes of 
human gastroenteritis) [34] to the chromosome of χ7122 
and confirmed it to be functional. The N-linked hepta-
saccharide glycan decorates around 50 periplasmic and 
surface proteins in its natural C. jejuni host [35], where 
abrogation of N-linked glycosylation causes proteome 
instability and impairs the ability of the bacteria to col-
onise poultry, highlighting an important function of 
this moiety [36, 37]. Because of its conservation across 
enteropathogenic Campylobacters [34], its key biological 
function [36–38], surface exposure [39], proven immu-
nogenicity in rabbits [34], recognition by a human lectin 
[40], and prior success in vaccine formulations [41–43], 
this glycan was chosen as a vaccine antigen for this 
study. The heptasaccharide was then coupled by the PglB 
enzyme to the chosen acceptor protein, a detoxified vari-
ant of the C. perfringens pore-forming toxin NetB, which 
was modified to be shuttled to the periplasm (where PglB 
functions) and to contain ten glycan acceptor sequons. 
NetB is associated with the pathogenesis of necrotic 
enteritis and a promising vaccine candidate, as demon-
strated by its prior use in a Salmonella-vectored vaccine 
[44].
The χ7122 pgl integrant expressing glycosylated NetB 
described herein was tested in a chicken model to assess 
in  vivo fitness and its ability to reduce Campylobacter 
colonisation of the caeca and to protect from respiratory 
APEC infection.
Results
Generation of a suicide plasmid for the chromosomal 
integration of C. jejuni protein glycosylation (pgl) locus 
in avian pathogenic E. coli
To generate a multivalent live vaccine candidate for poul-
try using PGCT, we elected to genetically engineer a 
well-studied strain of APEC to express the C. jejuni hep-
tasaccharide as a glycan antigen to reduce Campylobac-
ter colonisation of chicken intestines, and consequently 
decrease poultry-derived food poisoning. In order to 
avoid placing an excessive metabolic burden on the 
APEC vector and to avoid having to use selective antibi-
otics to culture the vaccine strain, we devised a strategy 
for chromosomal integration of the C. jejuni pgl locus 
in the genome of χ7122, serotype O78:H9 [45]. Previ-
ous studies have shown that expression of the pgl locus 
and glycosylation of the targeted proteins is achieved in 
E. coli K-12 strains when both components are expressed 
from plasmids under the control of the pgl endogenous 
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promoters and inducible promoters, respectively [24, 
28, 38, 41, 46]. More recently, the pgl genes have been 
integrated in the genome of E. coli K-12 MG1655 with 
demonstrated functionality and improved growth phe-
notypes, indicating that a single chromosomal copy of 
the C. jejuni glycosylation machinery is sufficient to per-
form N-linked glycosylation of chosen acceptor proteins 
in the absence of significant metabolic burden on cell 
growth [47]. To this end, we constructed a suicide vec-
tor carrying the C. jejuni pgl locus terminally marked 
with a kanamycin resistance cassette surrounded by flip-
pase recognition target (FRT) sites for flippase-mediated 
removal of the antibiotic marker. The tagged pgl locus 
was flanked by two ~ 1  kb long homology arms (IntUP 
and IntDN) for integration into the APEC recipient strain 
by allelic exchange. The homology arms result in the 
introduction of the pgl cassette into a pseudogene, with 
the loss of 12 bp of the pseudogene between genes gidB 
and atpI (bases 3993380 and 3997791), an integration site 
that was previously shown to promote efficient expres-
sion of a reporter protein [48]. pCVD442 was used as a 
suicide vector backbone as it carries a pir-dependent R6K 
origin of replication, requiring λpir + strains for its main-
tenance, and the sacB gene of Bacillus subtilis confer-
ring sensitivity to sucrose, allowing positive selection for 
double recombinants that have lost the vector and carry 
the endogenous copy of the target region [49]. A Gibson 
assembly reaction [50] with seven fragments spanning 
the IntUP and IntDN homology arms for integration, the 
pgl locus divided into three 5 kb pieces, the FRT-flanked 
kanamycin marker, and the linearised pCVD442 vector, 
was constructed, resulting in plasmid pSECpgl (Fig. 1a). 
The assembly was electroporated into competent E. coli 
S17-1 λpir cells. Eight transformants growing on selective 
agar containing ampicillin (pCVD442-encoded resist-
ance marker) and kanamycin (resistance marker tagging 
the pgl locus) were screened by colony PCR with prim-
ers amplifying the fragment junctions to assess plasmid 
assembly. The resulting PCR amplicons were analysed by 
1% DNA agarose gel electrophoresis, identifying colo-
nies 1 and 7 as correctly assembled clones given that all 
five amplicons showed the expected size (Fig. 1b). Puri-
fied pSECpgl plasmids from colonies 1, 6, and 7 were also 
checked by restriction digest with AhdI-SacII restric-
tion enzymes to confirm the integrity of the assembled 
plasmids. All three clones showed the expected restric-
tion pattern of fragments at 19,932 and 4371 bp (Fig. 1c), 
however only clones 1 and 7 were confirmed to be correct 
by paired-end Illumina sequencing. These two plasmids 
were compared against the expected in silico reference 
sequence to identify single nucleotide polymorphisms 
(SNPs) and insertion/deletion (indel) variants. Both plas-
mids had a single nucleotide base change from T to C, 
at base coordinate 19,014. This change was outside of the 
coding and regulatory regions of the plasmid; hence it 
was deemed acceptable.
Integration of the C. jejuni pgl locus in the APEC genome
The correctly assembled pSECpgl plasmid transformed 
into E. coli S17-1 λ pir cells was delivered by conjugation 
to the recipient APEC χ7122 strain generating χ7122 pgl 
integrants. APEC χ7122 is naturally resistant to nalidixic 
acid  (NalR) [45], while the donor S17-1 λ pir strain is sen-
sitive to it, thus the presence of this antibiotic counter-
selects against the donor strain. Kanamycin resistance 
 (KanR) is conferred by the tagged pgl locus, therefore it is 
indicative of its presence in the receiver strain. Merodip-
loids subject to a single recombination are sucrose 
sensitive owing to the presence of the sacB-encoded lev-
ansucrase. Following amplification of merodiploids in the 
absence of ampicillin selection for double recombinants 
that are resistant to sucrose (owing to loss of pCVD422 
and the endogenous copy of the target region), but which 
retain the  kanR -marked pgl region, were selected. To 
ensure plasmid backbone loss, clones were tested for 
ampicillin sensitivity  (AmpS). Ten  NalR,  KanR,  sucroseR, 
 AmpS colonies were screened by colony PCR with prim-
ers aligning to regions immediately upstream and down-
stream of the IntUP and IntDN homology arms, and 
primers aligning to either the beginning or the end of the 
tagged pgl locus (Fig. 2a, top). PCR products are ampli-
fied only if the tagged pgl locus has been inserted at the 
chosen location, thus wild-type (wt) APEC colonies 
were used as negative controls. Resulting PCR products 
(~ 1250 bp) were analysed by 1% DNA agarose gel elec-
trophoresis and confirmed integration of the pgl locus 
at the right site in all ten clones analysed (Fig.  2a). To 
further confirm this and exclude off-target secondary 
mutations occasionally associated with use of positive-
selection suicide vectors [51], both wt χ7122 and χ7122 
pgl integrant (four clones of PCR positive colonies) were 
sequenced using Illumina paired end sequencing with a 
target coverage of 100x. The wt strain sequence showed 
36 variants when compared to the published genome 
sequence, NZ_HE962388, while χ7122 pgl integrant 
showed 8 variants when compared to the wt (Additional 
file 2). Those included 6 deletions, 1 insertion and a SNP 
(Table 1). Six of these variants were found in intergenic 
region and pseudogenes, except for one found within the 
flgG gene and one within a hypothetical protein-encod-
ing gene. No variants were found within the integrated 
pgl locus.
RNA-Sequencing was then performed to understand 
whether the insertion of C. jejuni pgl locus in χ7122 alters 
the transcriptome. RNA-Seq libraries were prepared 
in triplicates from wt χ7122 cells and χ7122 pgl cells. 
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Differential gene expression analysis indicated that the 
chromosomal insertion of the pgl locus does not signifi-
cantly perturb the χ7122 transcriptome, as most of the 
differences observed in transcript expression levels are 
not significant (Fig. 2b). Where differences were detected, 
transcripts in χ7122 pgl were mostly upregulated in com-
parison to χ7122 wt, suggesting the introduction of a 
heterologous glycosylation pathway only modestly alters 
host strain metabolism (Fig.  2b). Five transcripts dem-
onstrated an adjusted p-value < 0.05 (shown in red), sug-
gesting statistically significant levels of differential gene 
expression when comparing χ7122 pgl and wt strains. 
Two transcripts—ycbC and gidA—had greater levels of 
expression in wt χ7122, whereas three—ygeV, folk and 
ycfC-demonstrated greater levels of expression in χ7122 
pgl integrants. Gene ontology analysis revealed no link 
between the biological function of these genes. Read 
alignment also confirmed transcription of the pgl locus, 
with 0.04% of reads aligning to genes located within the 
pgl locus (Additional file 1: Table S1).
Functional testing of χ7122 pgl integrants
After having confirmed integration of the intact pgl locus 
at the correct site, and its expression at the transcrip-
tional level, the next step was to confirm functionality 
of the integrated pgl locus. If functional, χ7122 pgl inte-
grants would now be able to synthesize all the enzymes 
needed for the sequential assembly of C. jejuni heptasac-
charide (GalNAc-α1,4-GalNAc-α1,4-[Glc-β-1,3]GalNAc-
α1,4-GalNAc-α1,4-GalNAc-α1,3-diNAcBac-β-1, where 
Fig. 1 Generation of a suicide plasmid for chromosomal integration of the C. jejuni pgl locus in APEC χ7122 via homologous recombination a 
Schematic representation of the cloning strategy used to construct the pSECpgl suicide vector used for integration of the C. jejuni pgl locus between 
genes gidB and atpI in APEC genome. A Gibson assembly reaction with seven fragments was assembled. IntUP (~ 1 kb left homology arm for 
integration), C. jejuni pgl operon consisting of 3 fragments of ~ 5 kb each (pgl1‑3), kanamycin selection marker surrounded by FRT sites, and IntDN 
(~ 1 kb right homology arm for integration) were PCR amplified and assembled into linearised pCVD442 plasmid between base coordinates 3633 
and 4253 replacing the IS1 element. b Junction PCRs to assess correct assembly of pSECpgl. Lanes 1 to 8—diagnostic junction PCR products from 
eight  AmpR,  KanR Gibson assembly transformants. The expected PCR product size along with primer pairs used are shown. Clones 1 and 7 showed 
expected PCR products for all five junction PCRs tested. c)Diagnostic restriction analysis of pSECpgl plasmids isolated from colonies 1, 6 and 7 
shown in b 
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GalNAc is N-acetylgalactosamine, Glc is glucose, and 
diNAcBac, a bacillosamine derivative, is 2,4-diaceta-
mido-2,4,6-trideoxyglucopyronose) onto the lipid carrier 
undecaprenyl-pyrophosphate exposed to the cytoplas-
mic side of the inner membrane [52]. After being flipped 
to the periplasmic side of the inner membrane [53], the 
undecaprenol-linked heptasaccharide would form a sub-
strate for the OST PglB, which transfers it to an aspar-
agine residue (N) within the glycosylation sequon D/
EXNXS/T (where X is any amino acid except proline) in 
the acceptor protein [26], and theoretically for the endog-
enous E. coli O-antigen ligase WaaL, which has relaxed 
specificity for its polysaccharides substrates [54]. A sche-
matic representation of a functional χ7122 pgl integrant 
is shown in Fig. 3a.
Firstly, to determine whether APEC χ7122 cells are 
capable of glycosylating acceptor proteins with the C. 
jejuni heptasaccharide, wt χ7122 strain was transformed 
with plasmid pACYC pgl (~ 10–12 copies per cell) con-
stitutively expressing the pgl locus [24] and with pEC415 
plasmids expressing glycosylatable versions of Pseu-
domonas aeruginosa ExoA toxoid, referred to as G-ExoA, 
upon L-arabinose induction. Acceptor protein G-ExoA 
carrying either two, G-ExoA(2) or ten, G-ExoA(10) gly-
cosylation sequons were chosen as they have been used 
extensively as carriers and as they are well expressed 
and soluble in periplasmic fractions enabling ease of gly-
coconjugate detection [20, 55, 56]. χ7122 with plasmid-
encoded pgl was able to N-glycosylate both versions 
of G-ExoA indicating functionality of the pgl locus in a 
pathogenic strain of E. coli (Additional file 1: Figure S1). 
Notably, glycosylation of G-ExoA(10) was more efficient 
and more easily detectable by SDS-PAGE followed by 
western blotting, thus this heavily glycosylatable version 
was chosen to test functionality of χ7122 pgl integrants 
bearing a single copy of the pgl locus.
χ7122 pgl integrants were transformed with the plasmid 
encoding inducible G-ExoA(10). Carrier protein expres-
sion and glycosylation were tested under different culture 
conditions, which led to the identification of variables 
that favour protein glycosylation in APEC χ7122 (Addi-
tional file  1: Figure S2). The expression of G-ExoA(10) 
was induced with L-arabinose at  OD600nm ~ 0.8. Cultures 
were grown overnight (ON) at 28  °C and G-ExoA(10) 
was purified the next day via periplasmic extraction or 
via His-pulldown from clarified whole cell lysates (WCL) 
followed by size separation by SDS-PAGE and western 
blotting. A soybean agglutinin (SBA) lectin was used 
to detect C. jejuni heptasaccharide as it binds to gly-
cans terminating with GalNAc residues, and an anti-His 
antibody was used to detect C-terminally His-tagged 
acceptor proteins. Western blotting results demonstrate 
all four χ7122 pgl integrants tested are capable of deco-
rating G-ExoA(10) with the C.jejuni glycan (Fig. 3b and 
c). However, the efficiency of χ7122 pgl in glycosylating 
the acceptor protein G-ExoA(10) amounts to only 4% of 
the positive control (+ ctrl) consisting of glycoengineer-
ing strain SDB1 expressing the pgl locus from pACYC 
pgl (Fig. 3d and Additional file 1: Figure S3). This differ-
ence is likely due to a combination of factors, including 
higher expression of the pgl locus from the pACYC pgl 
plasmid, more favourable glycan to protein coupling by 
PglB in SDB1 due to the lack of competition between dif-
ferent lipid-linked glycan substrates for PglB and WaaL, 
and possibly a lower metabolic burden as SDB1 is a 
W3110-derivative of E. coli K-12 lacking its own O-anti-
gen, the O-antigen ligase WaaL and the enterobacterial 
common antigen (ECA) initiating transferase WecA sav-
ing the cells the energy investment required to produce 
and ligate endogenous glycans [57].
Next, we interrogated whether χ7122 pgl could couple 
the heptasaccharide to the lipid A core via the endoge-
nous WaaL ligase. χ7122 pgl, χ7122 wt and E. coli K-12 
W3110 were cultured, harvested, washed and resus-
pended in optically transparent phosphate-buffered 
saline (PBS) to test surface exposure of the glycan antigen 
via dot-blotting. All χ7122 pgl integrants showed expres-
sion and surface exposure of their own O78 O-antigen, 
while no surface-exposed heptasaccharide was detected 
(Fig. 3e). O-antigen negative E. coli W3110 was used as a 
negative control for O78-antigen detection, and W3110 
with pACYC pgl was used as a positive control for surface 
exposure of the lipidA-linked heptasaccharide.
Assessing the in vivo fitness of χ7122 pgl integrants
To establish whether the heterologous expression of 
C. jejuni pgl locus in APEC χ7122 has a fitness cost, we 
assessed phenotypes of the sequenced χ7122 pgl integrant 
in vivo. Groups of 10 chickens were challenged with wt 
χ7122 and χ7122 pgl either individually via the intra-air 
(See figure on next page.)
Fig. 2 Generation of χ7122 pgl integrants. a Colony PCR confirmation of correct integration of the pgl locus into APEC χ7122 genome. Ten  NalR, 
 KanR,  sucroseR,  AmpS colonies were screened (lanes 1–10), χ7122 wt (lanes 11–12) was used as a negative control. Diagnostic junction amplicons 
1 and 2 (~ 1250 bp) confirm all 10 clones screened are correct. b Volcano plot displaying differentially expressed genes comparing χ7122 pgl to 
wt χ7122. Positive x axis represents up‑regulation in χ7122 pgl. Negative x axis represents up‑regulation in wt χ7122. Red points have adjusted 
p‑value < 0.05 0.04% of reads from χ7122 pgl libraries align to the C. jejuni pgl locus confirming its expression at the transcriptional level. Libraries 
were prepared in triplicate of PCR‑positive clone 2
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Fig. 2 (See legend on previous page.)
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Table 1 Filtered variants of χ7122 pgl integrant in comparison to its wild‑type counterpart
#Chrom Position Reference Alternative Variant type Feature
1 HE962388 472,203 CAA AAA AA CAA AAA A deletion intergenic
2 HE962388 824,578 GAA AAA A GAA AAA deletion pseudogene
3 HE962388 1,202,551 CGT CT deletion flgG
4 HE962388 1,747,220 GCCC GC deletion intergenic
5 HE962388 2,644,712 GAA AAA AA GAA AAA AAA insertion hypothetical protein
6 HE962388 3,999,175 GA G deletion intergenic
7 HE962388 4,305,775 ATTTT ATTT deletion intergenic
8 HE962388 4,305,829 G A SNP intergenic
Fig. 3 χ7122 pgl integrants express a functional N‑glycosylation system. a Schematic representation of an χ7122 pgl integrant and its function; 
b western blotting of  OD600nm normalised periplasmic extracts showing the four χ7122 pgl clones tested are capable of decorating a heavily 
glycosylatable version of acceptor protein G‑ExoA(10) with C. jejuni heptasaccharide, + ctrl consists of glycoengineering E. coli strain SDB1 
transformed with a plasmid encoding the pgl locus (pACYC pgl) and a plasmid expressing L‑arabinose inducible G‑ExoA(10) (this latter present in 
all other samples);− ctrl consists of χ7122 wt transformed with G‑ExoA(10)‑encoding plasmid. Percentage in parenthesis indicates sample loading 
(v/v) per lane; c western blotting showing results of a His‑pulldown from clarified lysates of the same samples shown in b; d densitometry analysis 
of b indicate χ7122 pgl integrants achieve ~ 4% glycosylation efficiency of G‑ExoA(10) in comparison to + ctrl, * indicates p < 0.05 (two‑tailed t‑test); 
e dot‑blotting of  OD600nm normalised cells washed and resuspended in PBS shows χ7122 pgl integrants maintain surface expression of their own 
O78 O‑antigen, while no detectable surface expression of C. jejuni glycan is observed. + ctrl and – ctrl for O78‑antigen detection are χ7122 wt and 
O‑antigen negative E. coli W3110, respectively. + ctrl and − ctrl for C. jejuni glycan detection are W3110 constitutively expressing the pgl locus from 
pACYC plasmid and χ7122 wt, respectively. The four clones of χ7122 pgl tested are those verified by sequencing
Page 9 of 26Mauri et al. Microb Cell Fact          (2021) 20:193  
sac route or in a 1:1 mixture of wt χ7122: χ7122 pgl orally. 
The challenge dose amounted to 3 ×  106  CFU resus-
pended in medium for intra-air sac delivery, and 1.5 ×  105 
or 1.5 ×  107 CFU for oral delivery (Fig. 4a and c). In the 
intra-air sac challenge model, birds were humanely culled 
8 h post-challenge as they exhibited moderate to severe 
signs of infection consistent with previous research 
using χ7122. Both χ7122 wt and χ7122 pgl colonised the 
lungs at similar levels of 4.49 ×  106 and 5.2 ×  106 CFU/g, 
respectively. As typical following intra-air sac inoculation 
with this strain, translocation to the liver and spleen was 
detected, but there was no significant difference in the 
colonisation of these tissues between strains (Fig.  4b). 
In the oral challenge model, robust colonisation of the 
caeca was observed at days 2 and 7 post-challenge in 
chickens challenged with both doses of mixed cultures of 
χ7122 wt and χ7122 pgl (Ec mix) with median total bac-
terial counts ranging from 4.8 ×  108 to 2.2 ×  109  CFU/g 
(Fig.  4d). From the competitive indices, where an index 
of 1 indicates equal fitness between χ7122 wt and χ7122 
Fig. 4 In vivo fitness and virulence of a χ7122 pgl integrant following intra‑air sac or oral challenge of chickens. a Experimental design of intra‑air 
sac challenge model; b Colonisation levels of χ7122 wt and χ7122 pgl in chicken lungs, liver and spleen were assessed 8 h post challenge; c 
Experimental design of oral challenge model; d Colonisation levels of mixed cultures of χ7122 wt and χ7122 pgl observed 2 days and 7 days 
post‑challenge with either  105 or  107 challenge doses in the caecum. Colonisation levels are expressed as  log10 CFU/g; e Competitive indices 
of χ7122 wt and χ7122 pgl in the caecum observed 2 and 7 days post‑challenge with either  105 or  107 challenge doses. Statistically significant 
differences are highlighted with * indicating p < 0.05 (Mann–Whitney U test). Data are presented as median values with 95% confidence intervals
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pgl; χ7122 pgl was found to be significantly attenuated at 
day 2 post-oral challenge but not at day 7 for both chal-
lenge doses tested (Fig.  4e). Livers were colonised very 
poorly. If bacteria were detected at all, the χ7122 pgl 
integrant was found in substantially lower numbers than 
the wt (data not shown). These results indicate modest 
attenuation of the χ7122 pgl integrant as compared to wt 
χ7122. Nevertheless, χ7122 pgl persists in the caecum for 
at least 7 days and appeared virulent via the respiratory 
route. It is acknowledged that attenuating mutations are 
likely to be needed to make an χ7122 pgl integrant suit-
able for field use, as for example with the aroA mutation 
in a current χ7122 O78 commercial vaccine [58]. How-
ever, as the χ7122 pgl strain colonises the chicken intes-
tine to high levels in the absence of overt pathology it 
was deemed suitable for pilot studies to determine if the 
vectored heptasaccharide glycan is protective against C. 
jejuni colonisation.
Generation of a trivalent live vaccine candidate
Having proven that χ7122 pgl is proficient in chicken gut 
colonisation without inducing colibacillosis, the next 
decision was which carrier protein we should select as an 
acceptor for the C. jejuni heptasaccharide glycan. Impor-
tant attributes of vaccine antigens are immunogenicity 
and surface exposure, thus we sought to identify a protein 
relevant for poultry pathology that would meet these cri-
teria. In this way, the protein would not only act as a car-
rier for the presentation of the glycan antigen but would 
also act as an immunological trigger and protective anti-
gen per se. Necrotic enteritis toxin B-like (NetB) from C. 
perfringens was identified as a suitable candidate. NetB 
is a key virulence factor of C. perfringens associated with 
severe outcomes of necrotic enteritis in chickens [59], a 
disease characterised by a sudden depression followed 
by a rapid increase in flock mortality that poses a signifi-
cant threat to the poultry industry [60]. The 3D crystal 
structure of NetB (Fig. 5a) revealed that NetB assembles 
as a heptamer to produce a pore-forming toxin capable 
of inserting itself in the membranes of target cells [61]. 
The authors of the study also identified a single amino 
acid mutation (W262A) that detoxifies the protein while 
preserving its ability to form the membrane-inserting 
heptamer [61], providing a useful construct well qualified 
for a subunit vaccine. Importantly, surface expression of 
NetB has been demonstrated in the host bacterium C. 
perfringens, and a Salmonella-vectored vaccine express-
ing NetB showed partial protection in a chicken model 
[44]. We modified the detoxified protein by adding a 
PelB leader signal at the N-terminus for transport to the 
periplasm of Gram-negative bacteria and two or ten con-
sensus glycosylation sequons (DQNAT), rendering the 
protein a PglB substrate suitable for use with PGCT. We 
refer to these glycosylatable versions of the protein as 
G-NetB(2) and G-NetB(10) (Additional file 1: Figure S4a). 
Similarly to G-ExoA(10), G-NetB(10) showed consider-
ably better glycosylation than G-NetB(2) in E. coli K-12 
glycoengineering strains as well as in χ7122 pgl integrants 
(Additional file 1: Figure S4b). Interestingly, the addition 
of ten glycosylation sequons improved significantly the 
solubility of the protein, thus subsequent work was per-
formed solely with G-NetB(10). As a control, an ungly-
cosylatable version, unG-NetB, was designed in which 
the glycan acceptor asparagine residues were mutated 
synonymously to glutamine residues (DQNAT DQQAT) 
as shown in Fig.  5b. Both G-NetB(10) and unG-NetB 
were cloned into a pEXT20 backbone [62] where a  Ptac 
promoter drives their high-level expression upon IPTG-
mediated induction. Expression of G-NetB(10) and unG-
NetB in the glycoengineering strain CLM24 cedA::pglB, 
carrying a chromosomal copy of IPTG-inducible PglB 
and using genes encoded by pACYC pglΔpglB for glycan 
assembly, showed glycosylation of the G-NetB(10) accep-
tor protein with eight individual bands stained by SBA 
lectin indicating glycosylation of G-NetB(10) at one to 
eight sites (Fig. 5c, lane 1). UnG-NetB exhibited no gly-
cosylation serving as a negative control (Fig.  5c, lane 2 
and 4). To our surprise, the χ7122 pgl integrant also effi-
ciently glycosylated G-NetB(10) to a similar extent as the 
CLM24 cedA::pglB strain (Fig. 5c, lanes 3). To understand 
if G-NetB(10) glycoprotein localises to the surface of E. 
coli cells, a dot-blot of PBS-washed O-antigen negative 
and WaaL negative E. coli cells expressing glycosylated 
G-NetB was performed, suggesting surface exposure of 
the glycoprotein (Fig. 5d). The absence of the O-antigen 
and its ligase, WaaL, ensures the protein signal (anti-
His) and glycan signal (SBA lectin) observed on the cell 
surface are solely due to exposure of G-NetB decorated 
with C. jejuni heptasaccharide. The CLM24 cedA::pglB 
glycoengineering strain was chosen for this experiment 
as its performance in glycosylating G-NetB was supe-
rior to W3110-derivative SDB1. Efficient glycosylation 
of G-NetB(10) by χ7122 pgl and surface exposure of 
this glycoprotein reinforced the choice of NetB as a car-
rier protein for our candidate trivalent vaccine with the 
potential to reduce APEC, Campylobacter and C. perfrin-
gens infections.
While inducible expression of G-NetB(10) from 
pEXT20 will ensure that the glycoprotein is present at 
the point of vaccination, it is not certain that the pro-
moter would be active in vivo in the absence of IPTG or 
endogenous lactose. To drive the constitutive expres-
sion of G-NetB(10) and unG-NetB during colonisa-
tion of chickens, the two constructs were cloned into 
the pFPV25.1 vector under the control of the S. Typh-
imurium promoter  PrpsM [63]. The promoter has been 
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proven to be active in APEC during respiratory infec-
tions [64] and in S. Typhimurium in the avian gut by 
driving the expression of fluorescent reporter proteins 
[65]. Performances of the constructs for inducible and 
constitutive expression of G-NetB(10) and unG-NetB 
were then compared in the χ7122 pgl integrant (Fig. 6a). 
Biomasses, measured as optical density at 600  nm 
 (OD600nm), of χ7122 pgl cultures grown overnight 
showed that χ7122 pgl expressing IPTG-inducible 
G-NetB(10)/unG-NetB from pEXT20 reached similar 
 OD600nm 16  h post-induction irrespective of the pres-
ence of the glycan antigen (Fig. 6b). Likewise, the χ7122 
pgl integrant constitutively expressing G-NetB(10)/
unG-NetB from pFPV25.1 reached similar cell bio-
mass after overnight culture, but their final  OD600nm 
were ~ 1.4 fold lower than χ7122 pgl expressing NetB 
Fig. 5 In vitro characterisation of a NetB‑C. jejuni heptasaccharide glycan conjugate expressed from an inducible promoter in E. coli CLM24 
cedA::pglB strain and χ7122 pgl. a Crystal structure of pore‑forming toxin NetB in its heptameric form (PDB: 4H56) [61]; b Schematic linear structures 
of NetB monomers modified to be suitable PglB substrates. G‑NetB(10) is a glycosylatable toxoid version N‑terminally fused to a PelB leader 
peptide for translocation to the periplasm, containing ten glycosylation sequons, and a C‑terminal 6xHis tag. unG‑NetB is the non‑glycosylatable 
counterpart where each sequon has a NQ mutation abrogating N‑linked glycosylation; c Western blotting showing results of a His‑pulldown of 
G‑NetB(10) and unG‑NetB from E. coli glycoengineering strain CLM24 cedA::pglB containing a chromosomal copy of PglB and a plasmid encoding 
the pgl genes necessary to produce C. jejuni heptasaccharide (pACYC pglΔpglB) in lanes 1–2, and χ7122 pgl integrant in lanes 3–4. Percentage in 
parenthesis indicates sample loading (v/v) per lane; d dot‑blot of  OD600nm normalised cells washed and resuspended in PBS shows G‑NetB(10) 
glycoconjugate is exposed on the cell surface in CLM24 cedA::pglB, O‑antigen negative and WaaL negative glycoengineering strain carrying pACYC 
pglΔpglB. IPTG induction that promotes the expression of both PglB and G‑NetB(10) in this strain is indicated with + , if present, or −, if absent
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from pEXT20 vectors, suggesting constitutive expres-
sion of NetB may be more burdensome for the cells 
(Fig. 6b). To verify the extent of glycoconjugate expres-
sion, cultures were harvested, lysed and glycoconju-
gates were purified via a His-pulldown followed by 
SDS-PAGE and western blotting (Fig. 6c). Both pEXT20 
and pFPV25.1 vector drove expression of G-NetB(10) 
and unG-NetB in χ7122 pgl, where G-NetB(10) was 
successfully glycosylated. OD-normalised densitom-
etry analysis of His-purified G-NetB(10) and unG-NetB 
triplicates of the samples shown in Fig. 6b indicate that 
the extent to which G-NetB(10) glycoconjugate is cou-
pled to the C. jejuni heptasaccharide is not significantly 
different when NetB expression is driven by either vec-
tor (Fig.  6d). Yet, the protein content of the glycocon-
jugate is ~ 1.9 fold lower when expression is achieved 
from pFPV25.1 rather than from pEXT20 vector 
(Fig.  6d), where constitutive expression of G-NetB(10) 
seems to favour formation of a more heavily glyco-
sylated protein (higher glycan/protein ratio, see upward 
shift on blot in Fig. 6c, and Additional file 1: Figure S5). 
The difference in protein expression is less pronounced 
for unG-NetB (Fig.  6e). A sandwich ELISA was per-
formed on all purified G-NetB(10) glycoconjugates and 
unG-NetB controls to assess protein glycosylation lev-
els with a technique other than densitometry. As ELI-
SAs are highly sensitive assays, smaller difference in 
glycan coupling could be detected with this method. 
ELISA results confirmed that G-NetB(10) glycosyla-
tion is achieved from either construct to a compara-
ble extent. To understand whether the NetB antigens 
localise to the surface of the χ7122 pgl vaccine strain an 
ELISA on whole cells washed and resuspended in PBS 
was performed (Fig.  6g). The results indicate that the 
χ7122 pgl vaccine strains are capable of localising G-/
unG-NetB on the cell surface, albeit they do so consid-
erably less efficiently than the glycoengineering CLM24 
cedA::pglB strain. Surface display of the C. jejuni hepta-
saccharide depends on the exposure of the G-NetB(10) 
glycoprotein in CLM24 cedA::pglB glycoengineering 
strain, which is ligase deficient. Given the vaccine strain 
is WaaL positive, it is possible that surface display of 
the glycan epitope is not solely due to presentation 
of G-NetB(10) glycoprotein, but also in part to lipid 
A-linked heptasacchride justifying the glycan levels 
detected above background in the vaccine strain lack-
ing NetB as well as in the strain delivering unG-NetB. 
On-cell western blotting (OCW) of fixed integer or 
permeabilised cells (Fig. 6h) showed that both G-NetB 
and unG-NetB are mostly localised in the periplasm 
of both CLM24 cedA::pglB strain and of the χ7122 pgl 
strain. While some copies of G-/unG-NetB are surface-
exposed in CLM24 cedA::pglB glycoengineering strain, 
surface display of G-NetB glycoprotein or its unglyco-
sylated counterpart, unG-NetB, is hardly detectable on 
the vaccine strain using this technique.
Evaluation of protection conferred by the trivalent vac-
cine candidate in poultry.
We first conducted a trial with the χ7122 pgl integrant 
expressing G-NetB(10) following IPTG induction from 
the pEXT20 vector as shown in Fig.  7. Groups of 20 
chickens were orally vaccinated at day 7 and day 21 post-
hatch with  107 CFU of the vaccine strain resuspended in 
LB medium (Fig. 7a). Mock-vaccinated birds were orally 
given LB medium only. At days 21 and 28, prior to sec-
ond vaccination and C. jejuni challenge, respectively, 
(See figure on next page.)
Fig. 6 Analysis of the glycoconjugate vaccine candidate in vitro. a Schematic representation of the glycoconjugate vaccine candidate and its 
unglycosylated counterpart serving as a negative control; b Estimated biomass of vaccine strains after overnight culture at 28 °C, values plotted are 
 OD600nm means ± standard deviations of triplicates; c SDS‑PAGE followed by western blotting of His‑purified G‑NetB(10) and unG‑NetB expressed 
in χ7122 pgl from either IPTG‑inducible pEXT20 or constitutive pFPV25.1 backbone, percentage in parenthesis indicates sample loading (v/v) per 
lane; d, e semi‑quantitative densitometry analysis of glycan and protein content of G‑NetB(10) glycoconjugates (d) and unG‑NetB control (e), values 
plotted are OD‑normalised mean intensities ± standard deviations of triplicates (see western blots in Additional file 1: Figure S5 for details), AU, 
arbitrary units; f Sandwich ELISA on purified glycoconjugate G‑NetB(10) and unG‑NetB control to relatively quantify the levels of heptasaccharide 
coupled to G‑NetB(10) carrier expressed from the χ7122 pgl strains. g Whole cell ELISA on the CLM24 cedA::pglB glycoengineering strain and χ7122 
pgl vaccine strains to relatively quantify the surface display of G‑NetB(10) and unG‑NetB. IPTG was used to induce NetB expression from pEXT20 
vector in the glycoengineering strain, NetB expression from pFPV25.1 in the vaccine strains is instead constitutive. The green dotted line represents 
a non‑specific signal detected when staining CLM24 cedA::pglB + pACYC pglΔpglB (left) and χ7122 wt cells (right) with SBA lectin. Values plotted in 
(f‑g) are background subtracted  OD450nm means ± standard deviations of three biological replicates. Background is set to zero, glycosylation signal 
of unG‑NetB constructs was below background. Panels c‑f are different analysis of the same set of triplicates. Statistically significant differences 
are highlighted with * indicating p < 0.05 (two‑tailed t‑test). h OCW on CLM24 cedA::pglB glycoengineering strain and χ7122 pgl vaccine strains to 
visually detect the surface display of G‑NetB(10) and unG‑NetB. Cell permeabilization was performed to detect NetB antigens localised into the 
periplasm. IPTG was used to induce NetB expression from pEXT20 vector in the glycoengineering strain, while NetB expression from pFPV25.1 in 
the vaccine strains is constitutive. Empty wells stained with both primary and secondary antibodies were used as negative controls (− ctrl), while 
O‑antigen negative, WaaL positive E. coli cells expressing pSECpgl were used as positive controls (+ ctrl) for surface display of the heptasaccharide 
(lipid‑linked surface glycan)
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Fig. 6 (See legend on previous page.)
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kanamycin resistant colonies inferred to be the χ7122 
pgl strain were isolated from the vaccinated chickens at 
median levels of 3 ×  106 CFU/g (Fig. 7b). Bacteria resist-
ant to both kanamycin and ampicillin were not recov-
ered (not shown), suggesting pEXT20 instability and 
loss in  vivo. No kanamycin resistant bacteria were iso-
lated from mock-vaccinated chickens confirming the 
lack of spread of the live vaccine between groups. At 
day 35, a week after challenge with 100 CFU of C. jejuni 
strain M1, kanamycin-resistant bacteria were recovered 
only from 7/10 vaccinated chickens at median levels of 
2.8 ×  106  CFU/g (Fig.  7b). C. jejuni M1 was recovered 
from vaccinated and mock-vaccinated chickens at 
median levels of 1.5 ×  109 and 3.9 ×  109  CFU/g, respec-
tively, resulting in a small, but statistically significant 0.42 
 log10 reduction in caecal carriage in the vaccinated chick-
ens (Fig. 7c).
A second trial was performed to assess protec-
tion conferred by χ7122 pgl constitutively expressing 
G-NetB(10) or its unglycosylatable control, unG-NetB, 
from the pFPV25.1 vector against both C. jejuni and 
APEC homologous challenge. The vaccine strains were 
confirmed to contain all four plasmids reported to be 
present in strain χ7122 by PCR for plasmid-encoded 
genes (Additional file 1: Figure S6) (66, 67). Upon vali-
dation, groups of 15 chickens were vaccinated orally 
or via the intra-air sac route at day 7 and day 21 post-
hatch with  107 or  103  CFU of the vaccine strains, 
respectively (Fig. 8a). A first group was vaccinated with 
the G-NetB(10) expressing strain, a second group with 
the unG-NetB expressing strain, and a third group was 
mock-vaccinated with PBS only. Birds were orally chal-
lenged at day 28 with 4 ×  105 CFU of C. jejuni 11168H 
and at day 36 with 7 ×  106  CFU of wt APEC χ7122 
intra-air sac. Reduction of C. jejuni and APEC coloni-
sation were assessed 1  week and 1  day post challenge, 
respectively. Similarly to the previous trial, birds chal-
lenged with wt χ7122 were humanely culled within 
a day as the mock-vaccinated birds began to exhibit 
moderate to severe signs of infection.
Oral vaccination with χ7122 pgl expressing G-NetB(10) 
reduced mean caecal colonisation by C. jejuni 11168H 
compared to the mock-vaccinated group by nearly 2  log10 
CFU, but the difference was not statistically significant 
owing to the variation in colonisation observed (Fig. 8b). 
No reduction was observed when the vaccine delivers 
Fig. 7 χ7122 pgl expressing G‑NetB(10) from pEXT20 fails to substantially reduce Campylobacter colonisation. a Experimental design; b Strain 
colonisation levels in the caeca of vaccinated chickens at days 21, 28 and 35. Retrieved vaccine strains were  NalR,  KanR only, indicating loss of 
 AmpR pEXT20‑G‑NetB(10) plasmid in vivo. c Colonisation levels of C. jejuni strain M1 in the caeca of vaccinated chickens one week after challenge. 
Colonisation levels of the caecum from either the live vaccine (b) or C. jejuni M1 (c) are expressed as  log10 CFU/g. Statistically significant reductions 
are highlighted with * indicating p‑values < 0.05 (Mann–Whitney U test). Data are represented as median values with 95% confidence intervals
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unglycosylated NetB, which suggests the modest protec-
tive effect is not associated with innate immune priming 
or competition by the χ7122 pgl strain per se. By contrast, 
no effect on caecal colonisation by C. jejuni was observed 
following intra-air sac vaccination (Fig. 8c).
Both oral and intra-air sac vaccination with χ7122 
pgl vaccine strain resulted in a statistically significant 
reduction in colonisation of the lungs by wt APEC χ7122 
in comparison to mock-vaccinated chickens (Fig. 8d and 
e).
To evaluate the antibody response to NetB antigens in 
vaccinated chickens, serological ELISA were performed 
using purified G-NetB(10) and unG-NetB as coating anti-
gens (Additional file 1: Figure S7) in order to discriminate 
Fig. 8 Efficacy of χ7122 pgl vaccine strains vectoring G‑NetB(10) or unG‑NetB against caecal colonisation by C. jejuni or lung colonisation by wt 
χ7122. a Experimental design; b, c Assessing reduction of C. jejuni 11168H colonisation of the caeca 1 week after challenge in b orally vaccinated 
chickens or c intra‑air sac vaccinated chickens; d, e Assessing protection against homologous challenge with wt χ7122 in d orally vaccinated 
chickens or e intra‑air sac vaccinated chickens. Colonisation levels of the caeca (for C. jejuni) and lungs (for wt χ7122) are expressed as  log10 CFU/g. 
Data are represented as median values with 95% confidence intervals. Statistically significant reductions are highlighted with * indicating p < 0.05 
(GLM followed by Dunn’s post hoc). † indicates animals that were euthanised on presentation of end‑point criteria specified in our licence for 
animal research
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responses directed against the glycoprotein and protein-
only, respectively (Fig. 9). While some birds that received 
χ7122 pgl vectoring glycosylated or unglycosylated NetB 
showed a moderate response relative to mock-vaccinated 
birds, considerable inter-animal variance was detected 
and consequently differences in median values proved 
not to be statistically different.
Discussion
As the poultry industry grows and consumption of poul-
try-derived products continues to increase worldwide, 
prevention of infectious diseases is critical to maintain 
healthy flocks and to limit the spread of zoonoses from 
this source. Concomitantly, the rise in antimicrobial 
resistance is posing serious threats owing to the wide-
spread use of antibiotics as therapeutics to control infec-
tions and as growth-promoters in farmed animals in 
some countries [68]. Expanding the vaccine portfolio for 
farmed animals is paramount for tackling this problem 
[69].
Veterinary vaccines need to be considerably cheaper 
than those for humans and easy to produce and adminis-
ter at scale [70]. A biotechnology like PGCT that exploits 
live bacterial cells as factories to produce glycoconjugates 
and is applicable to pathogenic strains offers new cost-
effective strategies for vaccine design well suited for the 
veterinary market.
In this study we presented a novel vaccine design cre-
ated using PGCT. By integrating the C. jejuni pgl locus 
into the genome of an APEC strain we demonstrate that 
the conserved heptasaccharide antigen from C. jejuni can 
be expressed and conjugated to recombinant acceptor 
proteins expressed from a plasmid in a pathogenic E. coli 
strain. The introduction of a heterologous glycan synthe-
sis pathway did not substantially alter the transcriptome 
Fig. 2b) or virulence following intra-air sac inoculation of 
chickens (Fig.  4a and b). In competition assays to study 
intestinal colonisation, the χ7122 pgl strain was slightly 
less fit Fig. 6 than the parent strain, but still colonised the 
gut effectively (Fig. 4d and f ). As the strain colonises the 
gut in the absence of colibacillosis, it was deemed suit-
able for pilot studies to assess protection conferred by 
the vectored antigen, accepting that further attenuating 
mutation is likely to be required to make it suitable for 
field deployment. We demonstrated that a single chro-
mosomal copy of the pgl locus in the χ7122 pgl strain 
efficiently glycosylates a sequon-tagged NetB similarly 
to an E. coli K-12 glycoengineering strain expressing the 
glycan assembly genes from a plasmid (Fig.  5c). Surface 
display of the antigen is limited in the χ7122 pgl strain 
(Fig.  6g and h), although the vaccine strain can still 
release copies of the antigen post lysis in vivo. Levels of 
antigen presentation are proportional to the efficacy of 
vaccines against the target pathogens [71], so achieving 
Fig. 9 Induction of immune responses to NetB antigens following vaccination and challenge by oral and intra‑air sac routes Antigen‑specific 
serum IgY against G‑NetB(10) (a, b) and unG‑NetB (c, d) were measured by indirect ELISA between first and second vaccine dose (day 21), between 
the second vaccine dose and challenge (day 28) and at post‑mortem examination (day 35). Data are represented as median values with 95% 
confidence intervals
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efficient glycosylation is a prerequisite for our candidate 
to work. This feature is very relevant for vaccines target-
ing Campylobacter spp., where differences in the glycan 
dose may explain differences in the efficacy of glycocon-
jugates tested thus far [72, 73].
We elected to express the conserved Campylobac-
ter heptasaccharide encoded by the pgl locus in APEC, 
as this antigen, unlike capsular polysaccharides and 
O-antigens, does not vary [34]. It has a demonstrable 
role in Campylobacter spp. ability to colonise its hosts 
[36]. Moreover it has already shown efficacy as a vac-
cine antigen in recombinant glycoconjugate vaccines [41, 
43]. Previously, cross-talk between bacterial glycosyla-
tion pathways has been demonstrated [74]. Since we did 
not affect the synthesis pathway of χ7122 endogenous 
glycans, such as its O-antigen and its ECA, a competi-
tion between endogenous and heterologous glycans may 
occur for coupling to protein acceptors and lipid anchors. 
We could not observe exposure of lipidA-linked hep-
tasaccharide on the surface of χ7122 pgl strains by dot-
blot (Fig.  3e). We speculate this could be simply due to 
a considerable difference in size of the two glycans, 
whereby the much bigger O78 O-antigen (~ 1–4 million 
Da) [75] could mask the lipidA-linked heptasaccharide 
(~ 1400  Da) [52]. Alternatively, the χ7122 WaaL ligase 
may largely favour transfer of its endogenous O-antigen, 
starting with a GlcNAc residue, over C. jejuni heptasac-
charide, starting with a diNAcBac residue. ELISA data 
on whole cells suggest a minor surface display of the 
heptasaccharide independent of NetB glycoprotein, thus 
likely anchored to lipids (Fig. 6g). We also cannot exclude 
that structural integrity of the C. jejuni heptasaccharide 
is affected. It is possible that the heptasaccharide starts 
with a GlcNAc reducing end sugar, transferred by E. coli 
initiating transferase WecA, instead of bacillosamine 
transferred by PglC initiating transferase. However, pre-
vious evidence demonstrated that the immunogenic resi-
dues of this small heptasaccharide are the terminal ones 
[34], supporting the potential of our design. By coupling 
this glycan to an immunogenic carrier protein, we also 
hoped to achieve activation of both humoral and cellu-
lar immune responses, as observed in humans vaccinated 
with subunit glycoconjugate vaccines, thereby increasing 
vaccine potency and the duration of protection [14].
We tested our trivalent vaccine candidate against 
APEC and C. jejuni; testing against C. perfringens is yet 
to be performed and is complicated by the difficulty of 
experimentally reproducing and quantifying necrotic 
enteritis in chickens. The vaccine expressing glycosylated 
G-NetB(10) from an IPTG-inducible pEXT20 vector 
caused 0.42  log10 reduction in caeca colonisation from 
C. jejuni strain M1 (Fig.  7c). However, biologically, this 
reduction is unlikely to reduce transmission of C. jejuni 
to humans via the food chain. The vaccine expressing 
glycosylated G-NetB(10) from pFPV25.1 vector pro-
tected chickens from respiratory challenge with the 
homologous APEC strain (Fig. 8d, e), however reduction 
of colonisation with C. jejuni was marginal (Fig.  8b, c). 
Interestingly, median colonisation of the chicken caeca 
was reduced by 2  log10 CFU with our χ7122 pgl integrant 
containing the pFPV25.1-encoded G-NetB(10) vaccine 
in comparison with the unglycosylated control APEC pgl 
pFPV25.1 unG-NetB when delivered orally (Fig. 8b). This 
result is encouraging as it suggests that the decrease in 
colonisation is specifically due to the exposure to the C. 
jejuni glycan antigen and not to non-specific effects of 
the immunisation (e.g. priming of innate responses by the 
vector strain or direct competition between the vector 
and C. jejuni). However, the levels of reduction observed 
across the chickens were variable and statistical signifi-
cance was not achieved. Similarly, antibody responses 
against the delivered antigens, G-NetB(10) or unG-NetB, 
were low in magnitude and not significantly higher than 
in the mock-vaccinated group (Fig. 9). We are currently 
investigating the effects of higher temperature, mimick-
ing chicken body temperature, on the expression and 
glycosylation of the studied antigens as we suspect this 
may be a reason behind unsatisfactory protection against 
Campylobacter. A limitation of our vaccine candidate is 
that so far we only have evidence of protection against 
the homologous APEC serotype, whereas colibacillosis is 
known to be associated with diverse serotypes and evi-
dence of cross-protection (and one or more attenuating 
mutations) would be needed for it to be commercially 
acceptable.
The candidate vaccine presented in this work is an 
innovative adaptation of PGCT using a live strain as 
a carrier for glycoconjugate vaccines. Modification of 
several APEC serotypes with the same methodology 
described here is possible. Moreover additional muta-
tions to the vector strain to promote vaccine biocon-
tainment [76], enhance bacterial lysis [77], and to boost 
production and surface exposure of the glycoconjugates 
would be advantageous and desirable for the applicability 
of this class of vaccines in the veterinary field.
Conclusions
In this study we produced a novel bacterial multivalent 
vaccine for poultry exploiting PGCT. The vaccine is a 
modified APEC strain carrying a copy of C. jejuni pgl 
locus in its genome and a plasmid-encoded acceptor pro-
tein (NetB). The strain was demonstrated to be able to 
express C. perfringens toxoid NetB heavily glycosylated 
with the C. jejuni heptasaccharide antigen. The vaccine 
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was successful in reducing colonisation of the lungs by 
the homologous APEC serotype and Campylobacter col-
onisation of the caeca was reduced in a glycan-specific 
manner albeit not statistically significantly. The vaccine 
requires further optimisation and evaluation against C. 
perfringens and Campylobacter in a manner that simu-
lates natural exposure, but it paves the way for the gen-
eration of a novel class of live glycoengineered vaccines 
suitable for the veterinary industry.
Methods
Bacterial strains, plasmids and growth conditions
Electrocompetent E. coli strains were transformed with 
plasmids encoding the chosen carrier protein, and if 
necessary, the C. jejuni glycan, and PglB (glycan, carrier 
protein and PglB OST) in 1  mm gap cuvettes at 2  kV, 
200 Ω and 25 µF. Strains were routinely grown in Lysog-
eny Broth (LB) or on LB agar at 37 °C with the required 
antibiotics at the following concentrations: 100  µg/ml 
ampicillin, 20 µg/ml nalidixic acid, 50 µg/ml kanamycin, 
100  µg/ml trimethoprim. E. coli DH5α were used as a 
host for cloning experiments.
C. jejuni strains M1 and NCTC11168H were routinely 
cultured on charcoal-cephoperazone-deoxycholate agar 
(CCDA) at 40  °C under microaerophilic conditions (5% 
O2, 5% CO2 and 90% N2). Liquid cultures were prepared 
in Mueller–Hinton (MH) broth equilibrated in a micro-
aerophilic atmosphere overnight before inoculation and 
incubation for 16  h with shaking at 400  rpm. For chal-
lenge of chickens, liquid cultures were adjusted based 
on a standard curve of CFU/ml relative to  OD600nm, with 
serial dilution where required to obtain the desired chal-
lenge dose. Inocula used in chicken studies were con-
firmed by retrospective plating of tenfold serial dilutions 
on CCDA and determination of viable counts after incu-
bation for 48 h.
The bacterial strains, plasmids and oligos used in 




The suicide donor plasmid, pSECpgl, carrying the 
C. jejuni pgl operon for integration into the genome 
of E. coli χ7122 was constructed by seven fragment 
assembly into the pCVD422 vector using the Gibson 
method. Briefly, the pCVD442 vector backbone, IntUP 
and IntDN (two ~ 1  kb homology regions for integra-
tion into the E. coli χ7122 genome), the pgl operon 
consisting of three fragments each of ~ 5  kb (Pgl1-3), 
and a gene encoding a kanamycin selection marker 
surrounded by FRT sited for FLP-mediated marker 
removal, were each designed to contain a 25  bp over-
lapping region between each adjoining junction. Each 
fragment was PCR amplified with Q5 polymerase 
using oligonucleotide primers listed in Additional 
file  1: Table  S2. The PCR amplified fragments were 
then assembled into the pCVD422 backbone using the 
NEB HiFi assembly kit (#2623, New England Biolabs) 
according to the manufacturer’s instructions. Assem-
bly reactions were transformed into electrocompetent 
E. coli S17-1 λ pir. Transformants were selected on LB 
agar with kanamycin (50 µg/ml). PCR screening, using 
primers listed in Additional file  1: Table  S2, was per-
formed after the transformation to identify positive 
clones. Plasmids from positive clones were isolated by 
plasmid miniprep kit (#27104, QIAprep Spin Miniprep 
Table 2 Bacterial strains used in this study
Strain Description or genotype Reference or source
E. coli S17‑1 λ pir Conjugative donor strain for maintenance and transfer of the suicide pgl donor plasmid, 
pSECpgl
[78]
E. coli χ7122 Genome‑sequenced spontaneous  NalR APEC O78:H9 ST23 strain isolated from the liver of a 
turkey with colibacillosis. Template for amplifying ~ 1 kb upstream (IntUP) and downstream 
(IntDN) homology arms for integration of the pgl locus marked with a kanamycin resistance 
cassette between 3,997,780 and 3,997,791 on the genome
[45]
E. coli χ7122 pgl χ7122 pgl integrant carrying C. jejuni pgl locus marked with a kanamycin resistance cassette 
between position 3,997,780 and 3,997,791 on the genome
This study
E. coli W3110 O‑antigen negative strain widely used as a safe laboratory E. coli K‑12 strain, wbbL‑, ƛ‑, rph-1, 
IN(rrnD-rrnE)1
[79]
E. coli SDB1 W3110‑derivative, ΔwaaL, ΔwecA [57]
E. coli CLM24 cedA::pglB W3110‑derivative, ΔwaaL with genomic integration of IPTG‑inducible C. jejuni PglB in cedA Abouelhadid et al., (manuscript 
in preparation)
E. coli DH5α Commercial strain used for cloning New England Biolabs, #C2987H
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Kit, Qiagen). Constructs were confirmed and validated 
by IIlumina paired end sequencing as described below.
Construction of G‑NetB/unG‑NetB‑encoding plasmids
C. perfringens NetB (Uniprot ID: A8ULG6) was geneti-
cally detoxified (W262A) as described in [61]. The 
sequence was further modified, with 2 or 10 engineered 
N-glycosylation sites, 5 at the N-terminus and 5 at the 
C-terminus (or 1 and 1), the native signal peptide was 
replaced by a PelB signal for secretion to the periplasm, 
and a C terminal 6xHis tag was added. unG-NetB was 
designed in the same way, except for the addition of 10 
non-functional glycosylation sequons. DNA-encoding 
the modified NetB versions was commercially syn-
thesised and subcloned into the pEXT20 vector by 
EcoRI-PstI restriction enzyme digest and ligation. G/
unG-NetB and the rpsM promoter were separately 
amplified and linked via overlapping PCR. The resulting 
amplicon was EcoRI-HindIII digested and subcloned 
into pFPV25.1.
pSECpgl sequence verification by Illumina paired‑end 
sequencing
Sequences of putative pSECpgl plasmids were analysed by 
Illumina paired-end 300 nt long read sequencing. Briefly, 
plasmid DNA from the PCR and restriction digest-pos-
itive colonies was fragmented to 400  bp length using 
Covaris M220 focused ultrasonicator. Fragmented plas-
mid DNA were tagged with sequencing adapters using 
NEBNext UltraII DNA Library Prep Kit for Illumina 
(#E7645, New England Biolabs). Tagged DNA was then 
cleaned with AMPure beads, and subsequently indexed 
with indexing primers with a 12-cycle PCR, cleaned 
with AMPure beads, then quantified by using NEBNext 
Library Quant Kit protocol (#E7630, New England Bio-
labs). Finally, 20 pM quantified libraries were loaded on 
a MiSeq paired end 2 × 300 nt (MiSeq reagent kitV3 (600 
cycles) and sequenced using an Illumina MiSeq run. Raw 
plasmid sequencing data are available upon request.
Adapter and low quality sequences were trimmed by 
cutadapt (version 1.16) and sickle tools respectively [83, 
84] for all sequencing data. Trimmed reads from each 
sample were mapped to an in silico generated reference 
plasmid, pSECpgl sequence using the Burrows Wheeler 
transform algorithm-mem (version 0.6) read mapper [85] 
and variants were called using SAMtools (version 1.6) 
mpileup function [86] with at least 100 × read depth. The 
output from the variant calling was then used to gener-
ate consensus calling and fasta file generation using 
bcftools consensus function [86] and seqtk seq function 
(to convert fastQ files to fasta files) [87]. Variant called 
Table 3 Plasmids used in this study
Plasmid Description Antibiotic 
resistance(s)
Reference or Source
pCVD442 Suicide donor plasmid based on R6K replicon and sacB sucrose counter selection 
marker
Amp [49]
pKD4 Template plasmid for amplification of kanamycin cassette flanked with FRT sites Kan [80]
pEC415 Plasmid for L‑arabinose inducible expression,  Para Amp [81]
pEXT20 Plasmid for IPTG inducible expression,  Ptac Amp [62]
pFPV25.1 Plasmid for constitutive expression,  PRpsm Amp [63]
pACYC pgl Plasmid encoding C. jejuni pgl locus, constitutive expression Cm [24]
pACYC pglΔpglB Plasmid encoding C. jejuni pgl locus depleted of OST PglB, constitutive expression Cm, Kan [46]
pEC415‑G‑ExoA(2) L‑arabinose inducible expression of His‑tagged Exotoxoid A with 2 PglB glycosylation 
sequons under DsbA periplsmic signal
Amp [82]
pEC415‑G‑ExoA(10) L‑arabinose inducible expression of His‑tagged Exotoxoid A with 10 PglB glycosylation 
sequons under DsbA periplsmic signal
Amp [56]
pSECpgl Suicide plasmid for genomic integration of C. jejuni pgl locus in APEC Χ7122 genome Amp, Kan This study
pEXT20‑G‑NetB(2) IPTG inducible expression of His‑tagged NetB toxoid with 2 PglB glycosylation sequons 
under PelB periplasmic signal
Amp This study
pEXT20‑G‑NetB(10) IPTG inducible expression of His‑tagged NetB toxoid with 10 PglB glycosylation 
sequons under PelB periplasmic signal
Amp This study
pEXT20‑unG‑NetB(10) IPTG inducible expression of His‑tagged NetB toxoid with 10 non‑functional PglB 
glycosylation sequons (NQ) under PelB periplasmic signal
Amp This study
pFPV25.1‑G‑NetB(10) Constitutive expression of His‑tagged NetB toxoid with 10 PglB glycosylation sequons 
under PelB periplasmic signal
Amp This study
pFPV25.1‑unG‑NetB(10) Constitutive expression of His‑tagged NetB toxoid with 10 non‑functional PglB glyco‑
sylation sequons (NQ) under PelB periplasmic signal
Amp This study
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consensus fasta files of each sample were then annotated 
using “Feature” function of SnapGene (version 5.2) using 
an in-silico generated pSECpgl plasmid as the reference 
sequence.
Integration of C. jejuni pgl locus into the genome of APEC 
χ7122
The bacterial strains used in this study are listed in 
Table 1. The integration of the C. jejuni pgl operon into 
the genome of APEC χ7122 was achieved by homologous 
recombination by conjugative delivery of the donor sui-
cide plasmid carrying the pgl operon. Briefly, conjugative 
donor strain, E. coli S17-1-λpir carrying pSEC-Pgl5 plas-
mid and the recipient strain, APEC χ7122 were grown 
to  OD600nm of 1.0, mixed at 1:1 ratio in a 200 µl volume 
and then washed once with 1 × sterile PBS at 3000  rpm 
for 3  min, resuspended in the 20  µl of 1 × PBS, spotted 
onto 0.45  µm pore size membrane filter (MF-Millipore 
0.45  µm filter, Millipore Sigma) preincubated on a LB 
agar plate. Spotted membrane filter on LB agar plate was 
incubated at 37  °C for 4  h to allow conjugation. After 
4  h of incubation, the mating filter was resuspended in 
1  ml LB broth, serially diluted and plated onto the LB 
agar containing kanamycin and nalidixic acid at 50 and 
25 µg/ml respectively to select co-integrants (only χ7122 
recombinants of pSECpgl will grow). Colonies that grew 
on the LB agar with kanamycin and nalidixic acid were 
patch plated onto LB agar containing kanamycin and 
5% sucrose to select for cells that had undergone a sec-
ond homologous recombination event which removes 
the vector sequence and leaves the pgl operon integrated 
in the chromosome. Colonies that were kanamycin and 
sucrose resistant were tested for loss of vector sequences 
by patch plating onto LB agar with ampicillin (100  µg/
ml). Finally, 10 colonies that were kanamycin and sucrose 
resistant, and ampicillin sensitive were confirmed by 
colony PCR for integration of the pgl operon terminally 
marked with kanamycin into the genome between base 
coordinates 3997780 and 3997791 using primers listed in 
the Table 2.
Whole genome sequencing of χ7122 pgl integrants
Whole genome sequences of χ7122 wt strain and χ7122 
pgl integrant were sequenced by Illumina paired end 300 
nt long reads. Briefly, genomic DNA from the wild-type 
strain and four clones of colony PCR positive χ7122 pgl 
integrants were fragmented to 400 bp length using Cova-
ris M220 focused ultrasonicator. Fragmented genomic 
DNA were tagged with sequencing adapters using NEB-
Next UltraII DNA Library Prep Kit for Illumina (#E7645, 
New England Biolabs). Tagged DNA was then cleaned 
up with AMPure beads, and subsequently indexed with 
indexing primers with a 12-cycle PCR, cleaned with 
AMPure beads, then quantified by using NEBNext 
Library Quant Kit protocol (#E7630, New England Bio-
labs). Finally, 20  pM quantified libraries were loaded 
on a MiSeq paired end 2 × 300 nt (MiSeq reagent kitV3 
(600 cycles) and sequenced in Illumina MiSeq run. Raw 
genome sequencing data are available upon request.
Adapter and low-quality sequences were trimmed 
by cutadapt (version 1.16) and sickle tools respectively 
for all sequencing data. Trimmed reads from wild-type 
strain were mapped to published reference genome, 
NZ_HE962388 [1] and pgl integrants were mapped to in 
silico generated reference, NZ_HE962388_Pgl sequence 
by Burrows Wheeler transform algorithm-mem (ver-
sion 0.6) read mapper and PCR duplicates were removed 
by using PICARD tools. The variants were called using 
SAMtools (version 1.6) mpileup function with at least 
100 × read coverage. Output from variant calling were 
then used to filter the variants at 100 × read depth using 
GATK variant filtration function. Finally, filtered variants 
were annotated by snpEff tool.
RNA‑sequencing
LB broth with appropriate antibiotics was inoculated 
1:1000 with an overnight culture of APEC χ7122 wt and 
χ7122 pgl. Three independent cultures were incubated 
until mid-log phase  (OD600nm 0.6–0.8) and harvested. 
RNA was extracted using the Qiagen miRNeasy kit (fol-
lowing manufacturer’s protocol) with an additional 5-min 
lysozyme lysis step prior to the addition of Qiazol. rRNA 
was depleted prior to sequencing library preparation 
and each library was sequenced to a depth of 10 million 
2 × 150 bp paired end reads.
Post sequencing data manipulation and analysis was 
completed using bowtie2, samtools, FeatureCounts [88], 
DeSeq2 [89] and R Studio. A reference genome file was 
generated using the χ7122 HE962388.1 genome file [45] 
and bowtie2. The RNAseq reads were aligned to this ref-
erence file using bowtie2. The aligned read counts for 
each gene feature were assessed using FeatureCounts, 
which provides an output file with each gene present in 
the genome and the number of reads associated with 
each gene. The DeSeq2 analysis pipeline (R package) was 
used to assess differential gene expression, with volcano 
plots being generated in Rstudio.
Glycoconjugate expression and purification
Overnight pre-cultures grown in LB media with the 
required antibiotics were diluted 1:100 in fresh 20 ml of 
LB media in 50 ml closed tubes. Cultures were grown at 
37  °C, 180  rpm to  OD600nm ~ 0.8 at which point expres-
sion of inducible proteins was promoted by the addition 
of 0.04 (w/v) L-arabinose (for pEC415 and pMAF10 vec-
tors) or by 1  mM IPTG (for pEXT20 vectors). Cultures 
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were then grown at 28  °C for further 16 h on an orbital 
shaker platform with a rotational speed of 180 rpm, fol-
lowed by cell harvesting by centrifugation at 5300 g, 4 °C 
for 15 min.
For His-purifications pellets were resuspended in 1 ml 
ice-cold lysis buffer (50  mM  NaH2PO4, 300  mM NaCl, 
and 10  mM imidazole, pH 8.0). Resuspended cells were 
subjected to six rounds of mechanical lysis using a Fast-
Prep™ homogeniser (30 s per cycle at a speed of 6 m/s). 
Lysates were clarified by centrifuging at max speed for 
10  min on a table-top centrifuge. Clarified lysates were 
incubated at 4  °C on a roller with 50  µl NiNTA resin 
(Qiagen). Samples were then transferred to paper filter 
spin cups (Pierce) and washed 5 × with 500  µl washing 
buffer (50  mM  NaH2PO4, 300  mM NaCl, 20  mM imi-
dazole pH 8.0). His-tagged proteins/glycoproteins were 
then purified by competitive elution with 100  µl high 
imidazole-containing buffer (50 mM  NaH2PO4, 300 mM 
NaCl, 250  mM imidazole pH 8.0). Glycoconjugate pro-
duction was verified by SDS-PAGE followed by western 
blotting and ELISA as described below.
Lysozyme-mediated periplasmic extraction was per-
formed according to [25]. Periplasmic extracts were then 
used for SDS-PAGE and western blot analysis.
SDS‑PAGE and western blotting
His-pulldowns and  OD600nm-matched periplasmic 
extracts were mixed with LDS sample buffer and dena-
tured at 95  °C for 10  min before being separated on 
4–12% bis–tris gels in MOPS or MES buffer (Invitro-
gen, USA). Gels were then electroblotted onto a nitro-
cellulose membrane, which was then washed in PBS 
with 0.1% Tween-20 (PBS-T) and incubated overnight 
at 4  °C shaking in PBS-T with biotin-conjugated SBA 
lectin (Vector Laboratories) at a 1: 5000 dilution and 
mouse anti-His monoclonal antibody (Thermo Fisher 
Scientific) at a 1: 5000 dilution to detect C. jejuni hepta-
saccharide and His-tagged carrier proteins, respectively. 
Blots were washed 3 × in PBS-T, followed by incuba-
tion for 30  min-1  h at room temperature with second-
ary streptavidin IRDye 800CW and goat anti-mouse IgG 
IRDye 680 (LI-COR Biosciences) at 1:5000 and 1:10,000 
dilution, respectively. After 3 final washes, fluorescent 
signals in two channels, 700 and 800 nm, were detected 
with an Odyssey CLx LI-COR detection system (LI-COR 
Biosciences). Subsequent semi-quantitative densitometry 
analysis of the glycoconjugates was performed using the 
Image Studio analysis tool (LI-COR Biosciences). For 
On-cell western blotting (OCW) cultures were harvested 
and washed 3 times with PBS, fixed with 4% paraformal-
dehyde (PFA) in PBS (pH 7.4) for 20 min at room temper-
ature (RT), washed 4 times with PBS,  OD600nm-matched 
and spotted in triplicates in a bottom clear 96-well plate. 
Cell permeabilization of permeabilised samples was 
performed as described in [90]. Cells were heat fixed 
and air-dried, washed with PBS-T (0.1% Tween-20) for 
2 min static and 2 min shaking at 500 rpm and blocked 
for 30 min at RT with Carbo-free blocking buffer per well 
(Vector Laboratories) followed by incubations with pri-
mary and secondary antibodies as described above both 
used at 1:500 dilutions spaced and followed by 3 washes 
in PBS-T prior to LiCOR acquisition of fluorescent 
signals.
Dot‑blotting
1  ml of  OD600nm-matched cultures was pelleted by cen-
trifugation at 12,100  g for 2  min. Pellets were washed 
3 × in PBS and resuspended in 100 µl PBS. 2–4 µl were 
spotted on a nitrocellulose (NC) membrane, let dry and 
incubated with the respective primary and secondary 
detection systems as described above.
Sandwich and whole cell ELISA
In sandwich ELISAs transparent polystyrol 96-well plates 
with high protein binding capacity (F96 MaxiSorp, Nunc) 
were coated with mouse anti-his monoclonal antibody 
(Thermo Fisher Scientific) diluted 1:1000 in PBS (100 µl/
well) and incubated overnight at 4  °C. Wells were then 
washed four times with 200  μl PBS-T (0.1% Tween-
20) for 2  min static and 2  min shaking at 500  rpm and 
blocked for 30 min at RT with 200 μl Carbo-free block-
ing buffer per well (Vector Laboratories). After blocking, 
wells were washed twice as described above and eluates 
from His-pulldowns were diluted 1:100 in PBS. 50  µl/
well of diluted eluates were added to the plate and incu-
bated for 1  h at 37  °C. Unbound sample was removed 
with four washes performed as described above. Semi-
quantitative analysis of the glycan content of His-purified 
Campylobacter glycoconjugates were performed using 
biotin-conjugated SBA lectin (Vector Laboratories) at 
a 1: 1000 dilution in PBS-T (100 µl/well). The plate was 
incubated for 30 min at RT, 500 rpm. Unbound lectin was 
removed by four washes as previously described. Strepta-
vidin-HRP (Invitrogen) was added at 1:10,000 dilution in 
PBS-T (100 µl/well). The plate was incubated for 30 min 
at RT, and unbound antibodies were removed by four 
washes. ELISA plates were developed with 100  µl/well 
Tetramethylbenzidine (TMB) substrate solution (Inv-
itrogen). The oxidative reaction was stopped by adding 
100 µl/well  H2SO4 (2 N) and optical densities at 450 nm 
were detected using a SpectraMax iD5 plate reader 
(Molecular Devices).  OD450nm background values (buffer 
only in wells treated with bioSBA lectin and streptavidin-
HRP) were subtracted from test values. Technical and 
biological triplicates were averaged, values represent 
the arithmetic mean and error bars represent standard 
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deviations of biological triplicates. For whole cell ELI-
SAs, cultures were harvested, washed and resuspended 
in PBS to  OD600nm ~ 0.4. Cell resuspensions were spot-
ted in triplicates in transparent polystyrol 96-well plates 
(F96 MaxiSorp, Nunc) at 100 µl/well and incubated over-
night at 4  °C. Blocking, washes, primary and secondary 
antibodies staining and development were performed as 
described above. Surface display of NetB was detected 
with anti-His at 1:2000 dilution followed by anti-mouse 
IgG-HRP at 1:10,000. Surface display of C. jejuni hep-
tasaccharide was detected with SBA lectin as described 
above.
Animal experiments
White Leghorn chickens from Campylobacter-free flocks 
were obtained on the day of hatch from a Home Office 
licensed breeding establishment and housed in groups 
of up to twenty in colony cages. Groups were of mixed 
sex and individuals were wing-tagged for identification. 
Water and sterile irradiated feed based on vegetable pro-
tein (DBM Ltd., UK) were provided ad  libitum. Animal 
experiments were conducted at the Moredun Research 
Institute according to the requirements of the Animals 
(Scientific Procedures) Act 1986 under project licence 
PCD70CB48 with the approval of the local Animal Wel-
fare & Ethical Review Board. Chickens were monitored 
twice daily, or at least every 3  h when birds presented 
signs of colibacillosis. Post-mortem examinations were 
conducted following culling by cervical dislocation.
Determining the in vivo fitness of the APEC pgl integrant
Fitness of individual strains was determined in an intra-
air sac challenge model in which groups of ten chickens 
were directly inoculated in the air sac with 100 μl of cul-
ture containing 3 ×  106  CFU of the χ7122 wt or χ7122 
pgl strain. Post-mortem examinations were performed at 
8 h post-challenge on the appearance of clinical signs of 
colibacillosis. The lungs were collected to determine net 
replication close to the site of inoculation and the liver 
and spleen were collected to quantify systemic translo-
cation. 0.5  g of tissue was homogenised in 4.5  ml PBS. 
Serial dilutions of the homogenates were plated on LB 
agar with strain-appropriate antibiotics and incubated 
overnight at 37 °C to determine the viable counts. Fitness 
of strains was also tested in an oral challenge model in a 
competition assay in which groups of 10 chickens were 
orally gavaged with 100  μl of a mixed culture contain-
ing 1.5 ×  105 and 1.5 ×  107 CFU of both χ7122 and χ7122 
pgl. Post-mortem examinations were performed for five 
chickens from each group at 2 and 7 days post-challenge. 
The caecal contents and livers were collected, serially 
diluted as above and plated on both LB agar with only 
nalidixic acid to enumerate both χ7122 and χ7122 pgl and 
LB agar with nalidixic acid and kanamycin to enumerate 
only χ7122 pgl. Plates were incubated overnight at 37 °C 
to determine the viable counts from which the com-
petitive indices were calculated as the ratio of mutant to 
wild-type in output pools divided by the ratio of mutant 
to wild-type in the challenge inoculum.
Vaccination with χ7122 pgl pEXT20‑G‑NetB(10)
χ7122 pgl pEXT20-G-NetB(10) was grown overnight 
at 37  °C in LB broth Lennox, diluted 1:100 in fresh 
broth with the required antibiotics and grown until an 
 OD600nm ~ 0.8 was reached. At this point G-NetB(10) 
expression from pEXT20 was induced with 1  mM 
IPTG and the cultures were incubated at 28  °C shaking 
(180 rpm) overnight. The next day cultures were diluted 
to approximately  108  CFU/ml and glycoprotein pro-
duction in this challenge inoculum was confirmed by 
western blotting. To evaluate the efficacy of χ7122 pgl 
pEXT20-G-NetB(10) as a vaccine against caecal coloni-
sation by C. jejuni strain M1, chickens were orally vac-
cinated with 100  μl of this culture containing  107  CFU 
at days 7 and 21 of life. Mock vaccinated chickens were 
orally gavaged with 100 μl LB broth. At day 21, before the 
second vaccination, and at day 28, before challenge with 
C. jejuni M1, post-mortem examinations were performed 
for three or four chickens per group to determine coloni-
sation levels of χ7122 pgl pEXT20-G-NetB(10). The cae-
cal contents were collected, serially diluted and plated on 
LB agar with only kanamycin to detect the vaccine strain 
and kanamycin and ampicillin to confirm maintenance 
of pEXT20-G-NetB(10). Plates were incubated overnight 
at 37  °C to determine the viable counts. Liquid cultures 
of C. jejuni M1 were prepared as above and diluted to 
obtain a challenge dose of 100 CFU. Chickens were orally 
gavaged with this inoculum at day 28 and post-mortem 
examinations were performed on day 35. The caecal con-
tents were collected, serially diluted and plated on CCDA 
agar to determine colonisation levels of C. jejuni M1.
Vaccination with χ7122 pgl pFPV25.1‑G‑NetB(10)/unG‑NetB
Ninety chickens were divided into three vaccination 
groups according to the vaccine strain administered: 
χ7122 pgl pFPV25.1-G-NetB(10), χ7122 pgl pFPV25.1-
unG-NetB and mock-vaccinated group. Each group was 
housed in a different room to prevent cross contamina-
tion between vaccination strains and further divided 
into four subgroups of: (a) 10 birds vaccinated orally 
and challenged with C. jejuni 11168H, (b) 10 birds vac-
cinated by the intra-air sac route and challenged with 
C. jejuni 11168H, (c) 5 birds vaccinated orally and chal-
lenged with wild type χ7122, and (d) 5 birds vaccinated 
by intra-air sac and challenged with wt χ7122. Orally vac-
cinated chickens were inoculated with 100 μl of χ7122 pgl 
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pFPV25.1-G-NetB(10) or χ7122 pgl pFPV25.1-unGNetB 
containing  107  CFU at days 7 and 21 of life. Mock vac-
cinated chickens were orally gavaged with 100 μl of PBS. 
At the same time points, two additional groups were vac-
cinated by the intra-air sac route with 100 μl of the vac-
cine strains containing  103 CFU of the APEC strains and 
mock-vaccinated chickens were treated with 100  μl of 
PBS. At day 28, ten chickens that were vaccinated orally 
or by the intra-air sac route were challenged by oral gav-
age with 4 ×  105 CFU of C. jejuni 11168H. Post-mortem 
examinations of these chickens were performed at day 
35 as described above and the caecal contents were col-
lected, serially diluted and plated on CCDA agar to 
determine colonisation levels of C. jejuni 11168H. At 
day 36, the remaining five chickens in each group were 
challenged by the intra-air sac route with 100  μl of E. 
coli χ7122 wt containing 7 ×  106  CFU. Post-mortem 
examinations of these chickens were performed at day 
37 as described above. The lungs were collected, serially 
diluted and plated on MacConkey agar to determine col-
onisation levels of E. coli χ7122.
Serological ELISA
Blood was collected by cardiac puncture at post-mor-
tem (PM) examination and serum was stored at − 80 °C 
following centrifugation of clotted blood at 1000  g 
for 10  min at 4  °C. Serum IgY levels were quantified 
by ELISA as described. To quantify vaccine-specific 
responses, 96-well plates were coated with 0.1  μg/ml of 
purified unG-NetB or G-NetB(10) antigens in carbonate-
bicarbonate buffer and incubated at 4 °C overnight. Plates 
were washed three times with PBS containing 0.05% (v/v) 
Tween 20 and 50  μl of 1:50 serum diluted in PBS was 
added per well. Control wells were maintained to which 
no serum was added. Plates were incubated at room tem-
perature for 1 h and then washed as above. Rabbit anti-
chicken IgY-horseradish peroxidase (HRP) antibody at 
1:3000 (Sigma, UK) was used to detect bound serum IgY. 
Plates were washed three times, tetramethylbenzidine 
(TMB) substrate (BioLegend, UK) was added and the 
plates were incubated for 10 min at room temperature in 
the dark. The reaction was stopped using 2 M  H2SO4 and 
optical density at 450  nm adjusted against optical den-
sity at 620 nm  (OD450/620 nm) was measured using a plate 
reader (Biotek Cytation 3) with background correction 
using the values of the no serum control wells.
Statistical analysis
Statistical analyses of competitive indices and differences 
in colonisation between groups of pEXT20-G-NetB(10) 
vaccinated and mock-vaccinated chickens were per-
formed in GraphPad Prism version 8.00 (GraphPad Soft-
ware) using the Mann–Whitney U test. P values < 0.05 
were considered to be statistically significant. Data are 
represented graphically as median values with 95% con-
fidence intervals. Bacterial counts for unbalanced data 
from the animal trial using pFVP25.1-based vaccines 
were analysed in Minitab version 19 (Minitab, LLC), 
using a general linear model (GLM) and post-hoc Dun-
nett method. Two tailed t-tests for analysis of densitom-
etry and ELISA data were performed using Microsoft 
Excel (version 2013).
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Additional file 1: Figure S1. Exploiting G‑ExoA constructs to test N‑linked 
glycosylation in χ7122. (a) Schematic representation of carrier protein 
ExoA genetically detoxified and modified with either two, G‑ExoA(2), or 
ten ,G‑ExoA(10), PglB glycosylation sequons. (b) SDS‑PAGE followed by 
western blotting showing results of a His‑pulldown from χ7122 express‑
ing G‑ExoA(2) or G‑ExoA(10) and the pgl locus from pACYCpgl plasmid. 
Glycosylation increases as the number of glycosylation sequons increases, 
facilitating detection of glycosylation with G‑ExoA(10). The negative 
control (‑ ctrl) consists of χ7122 expressing G‑ExoA(10) in absence of the 
pgl locus. Percentage in parenthesis indicates sample loading (v/v) per 
lane. Figure S2. Identification of conditions that favour protein glyco‑
sylation in the χ7122 pgl integrant. (a) SDS‑PAGE followed by western 
blotting showing results of a His‑pulldown from the χ7122pgl integrant 
transformed with a plasmid‑encoded L‑arabinose inducible G‑ExoA(10) 
carrier protein. Differences in culture conditions are enlisted in the table 
below the blot. (b) SDS‑PAGE followed by western blotting showing 
results of a His‑pulldown from either glycoengineering strains SDB1 or 
χ7122 pgl integrant transformed with a plasmid‑encoded L‑arabinose 
inducible G‑ExoA(10) carrier protein and with pACYCpgl for SDB1. Both 
strains were cultured in either LBB Lennox or 2YT‑M9 media to assess 
their effect on glycosylation. The most favourable conditions for protein 
glycosylation in χ7122 pgl were identified as cultures setup in a closed 
system (20 ml in 50 ml tube), induction of carrier protein expression at late 
exponential phase (OD600 ~0.8), growth post induction at 28°C shaking in 
LBB Lennox medium. Percentages in parenthesis indicate sample loading 
(v/v) per lane. Figure S3. Testing functionality of χ7122 pgl integrants. 
SDS‑PAGE followed by western blotting of periplasmic extracts shown in 
Figure 3b. Fluorescent signals were acquired from single channels at 680 
nm wavelength for the protein (anti‑His) and 800 nm for the glycan (SBA 
lectin). The boxes highlighted were used for semi‑quantitative densi‑
tometry analysis of protein and glycan levels. Percentage in parenthesis 
indicates sample loading (v/v) per lane. Figure S4. Assessing G‑NetB as 
a carrier protein. (a) Schematic representation of carrier protein NetB 
genetically detoxified and modified with either two, G‑NetB(2), or ten, 
G‑NetB(10), PglB glycosylation sequons. (b) SDS‑PAGE followed by western 
blotting showing glycosylation of G‑NetB(2) or G‑NetB(10) by a χ7122 pgl 
integrant and the glycoengineering strains used as controls. Lanes 1‑2 
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SDB1 cells expressing G‑NetB(2), lane 3 CLM24 cedA::pglB cells expressing 
G‑NetB(10), lanes 4‑5 SDB1 cells expressing G‑NetB(10), lanes 6‑7 χ7122 
pgl expressing G‑NetB(2) and G‑NetB(10). pACYCpglΔpglB (in lanes 2 and 
5) serves as a negative control on protein glycosylation. In strain CLM24 
cedA::pglB (lane 4) pACYCpglΔpglB provides pgl genes responsible for the 
glycan assembly, while an IPTG‑inducible copy of PglB is chromosomally 
integrated. Figure S5. Expression of inducible and constitutive G‑NetB/
unG‑NetB from biological triplicates of χ7122 pgl vaccine strains. (a) SDS‑
PAGE followed by western blotting showing results of a His‑pulldown of 
biological triplicates of χ7122 pgl vaccine strain expressing G‑NetB. Lanes 
1‑3 G‑NetB expressed from IPTG‑inducible pEXT20 backbone, lanes 4‑6 
from constitutive pFPV25.1 backbone; (b) SDS‑PAGE followed by western 
blotting showing results of a His‑pulldown of biological triplicates of 
χ7122 pgl vaccine strain expressing unG‑NetB as a negative control on 
glycosylation. Lanes 1‑3 unG‑NetB expressed from IPTG‑inducible pEXT20 
backbone, lanes 4‑6 from constitutive pFPV25.1 backbone. Percentages in 
parenthesis indicate samples loading (v/v) per lane. Figure S6. PCR valida‑
tion of the vaccine strains. Agarose gel showing PCR amplicons validating 
the presence of four endogenous plasmids of strain χ7122 (lanes 1‑4) and 
carrier protein‑encoding plasmid pFPV25.1‑G‑NetB(10) in the G‑NetB(10) 
vaccine strain (lane 5, left), and unG‑NetB in the unglycosylatable control 
(lane 5, right). Figure S7. Purified G‑NetB(10) and unG‑NetB for use 
as coating antigens in serological ELISAs. Comassie (a) and SDS‑PAGE 
followed by western blotting (b) of purified fractions of G‑NetB(10) and 
unG‑NetB. The glycoprotein and its unglycosylated control where purified 
by His‑affinity chromatography and anion exchange on an AKTÄ purifier, 
followed by size exclusion chromatography using PD‑10 gravity columns. 
Fraction 1 of G‑NetB(10), which is entirely glycosylated at 1 to 10 sites and 
has no degradation product was used in ELISA together with unG‑NetB 
to quantify antibody responses against the glycoprotein and protein‑only, 
respectively. 1 µg/lane was loaded. Table S1. RNA‑Seq: number of reads 
assigned to each gene within the pgl locus. Table S2. Oligos used in this 
study
Additional file 2: WGS of χ7122 and χ7122 pgl summary
Acknowledgements
The authors acknowledge funding from BBSRC. All figures were created with 
BioRender.com.
Authors’ contributions
JC, BW, AG, and MS conceived and supervised the study. MM structured and 
wrote the manuscript, functionally tested χ7122 pgl integrants and designed 
G‑NetB(10) (Figs. 3, 5–6, Additional file 1: Figures S1–S5, S7). TS generated 
χ7122 pgl integrants (Figs. 1–2). PV planned, performed and analysed data 
from animal trials shown in Figs. 4, 7 and RCT the ones shown in Figs. 8–9 and 
Additional file 1: FigureS6. CCU and AB contributed to the animal experiments. 
AS performed RNA‑Seq of χ7122 pgl strains. VT cloned G‑NetB(2). SA gener‑
ated the CLM24 cedA::pglB strain. TS, PV, RCT and AS contributed text for the 
manuscript. All authors have read, edited and approved the final version of the 
manuscript.
Funding
The authors gratefully acknowledge funding from the Biotechnology & 
Biological Sciences Research Council (BBSRC; grant reference BB/N001591/1). 
MS also acknowledges support from the BBSRC Institute Strategic Programme 
on Control of Infectious Diseases (BB/P013740/1) and its constituent project 
BBS/E/D/20002174.
Availability of data and materials
Genome sequence data and raw RNA‑Seq data for the χ7122 pgl integrant 
are available on request and are in the process of submission to the European 
Nucleotide Archive (https:// www. ebi. ac. uk/ ena). Accession numbers will be 
added to the final version of the manuscript. Primary data and images from 
experiments are available for scrutiny on request. They will be held on secure 
servers for at least 10 years in accordance with funder requirements. Materials 
will be made available at no cost but may be subject to a Material Transfer 
Agreement owing to associated Intellectual Property. We may seek a contribu‑
tion toward the cost of biosecure shipment of live materials.
Declarations
Ethics approval and consent to participate
Animal experiments were conducted at the Moredun Research Institute 
according to the requirements of the Animals (Scientific Procedures) Act 
1986 under project licence PCD70CB48 with the approval of the local Animal 
Welfare & Ethical Review Board.
Consent for publication
All authors have read and approved the final version of the manuscript.
Competing interests
The authors declare no competing interests.
Author details
1 Department of Infection Biology, London School of Hygiene and Tropical 
Medicine, Keppel Street, London WC1E 7HT, UK. 2 Department of Veterinary 
Medicine, University of Cambridge, Madingley Road, Cambridge CB3 0ES, 
Cambridgeshire, UK. 3 The Roslin Institute, University of Edinburgh, Easter Bush 
Campus, Midlothian, Edinburgh EH25 9RG, UK. 4 Institute for Immunology 
and Infection Research, School of Biological Sciences, University of Edinburgh, 
Charlotte Auerbach Road, Edinburgh EH9 3FL, UK. 
Received: 10 May 2021   Accepted: 17 September 2021
References
 1. FAO. Overview of global meat market developments in 2019. Food and 
Agriculture Organization of the United Nations. 2020.
 2. Roser M, Ritchie H. Meat and dairy production. Our world in data. 2019 
[cited 2021 Apr 12]. p. 1–35. https:// ourwo rldin data. org/ meat‑ produ 
ction# per‑ capita‑ meat‑ consu mption.
 3. FAO F and AO. Production | Gateway to poultry production and products 
| Food and Agriculture Organization of the United Nations. 2021 [cited 
2021 Apr 12]. http:// www. fao. org/ poult ry‑ produ ction‑ produ cts/ produ 
ction/ en/.
 4. Dinev I. Diseases of poultry: a colour atlas. 2007. p. 81–85.
 5. Behravesh CB. Do backyard chickens pose any health risks to humans? 
WSAVA, One Health Commitee, CDC, 2018 [cited 2021 May 9]. https:// 
wsava. org/ wp‑ conte nt/ uploa ds/ 2020/ 01/ Clini cian‑s‑ Brief‑ March‑ 2018‑ 
TP‑ Backy ard‑ Chick ens. pdf.
 6. Food Safety Authority E, Boelaert F, Stoicescu A, Amore G, Messens 
W, Hempen M, et al. The European Union One Health 2019 Zoonoses 
Report. EFSA J. 2021;19(2):6406.
 7. Zoonoses report UK 2015. DEFRA, Public Health England, 2017 [cited 
2021 May 9]. https:// assets. publi shing. servi ce. gov. uk/ gover nment/ uploa 
ds/ system/ uploa ds/ attac hment_ data/ file/ 740920/ UK_ Zoono ses_ report_ 
2015. pdf.
 8. WHO Publishes list of bacteria for which new antibiotics are urgently 
needed. Vol. 38, Saudi Medical Journal. 2017 [cited 2021 Apr 22]. p. 444. 
https:// www. who. int/ news/ item/ 27‑ 02‑ 2017‑ who‑ publi shes‑ list‑ of‑ bacte 
ria‑ for‑ which‑ new‑ antib iotics‑ are‑ urgen tly‑ needed.
 9. World Health Organization. Research priorities for zoonoses and margin‑
alized infections. World Health Organization technical report series. 2012.
 10. CDC. Prioritizing zoonotic diseases for multisectoral, one health collabo‑
ration in the United States. 2019 [cited 2021 May 9]. https:// www. cdc. 
gov/ onehe alth/ pdfs/ us‑ ohzdp‑ report‑ 508. pdf.
 11. World Health Organization. WHO recommendations to reduce risk of 
transmission of emerging pathogens from animals to humans in live 
animal markets or animal product markets. 2020 [cited 2021 May 9]. 
https:// apps. who. int/ iris/ bitst ream/ handle/ 10665/ 332217/ WHO‑ 2019‑ 
nCoV‑ Human_ animal_ risk‑ 2020.2‑ eng. pdf? seque nce= 1& isAll owed=y.
 12. Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new 
developments. Vol. 21, Nature reviews immunology. Nature research; 
2021. p. 83–100.
 13. World Health Organization. Immunization coverage. Fact sheet. 2019 
[cited 2021 Apr 13]. p. 1. https:// www. who. int/ en/ news‑ room/ fact‑ 
sheets/ detail/ immun izati on‑ cover age.
Page 25 of 26Mauri et al. Microb Cell Fact          (2021) 20:193  
 14. Rappuoli R. Glycoconjugate vaccines: principles and mechanisms. Sci 
Transl Med. 2018;10(456):eaat4615.
 15. Citron KM, Lunn JA. Immunisation against infectious disease. Vol. 297, 
BMJ (Clinical research ed). 1988. p. 1406.
 16. Goebel WF, Avery OT. Chemo‑immunological studies on conjugated 
carb ohydrate‑proteins: I. The synthesis of p‑aminophenol β‑glucoside, 
p‑aminophenol βgalactoside, and their coupling with serum globulin. J 
Exp Med. 1929;50(4):521–31.
 17. Ishioka GY, Lamont AG, Thomson D, Bulbow N, Gaeta FCA, Sette A, et al. 
Major histocompatibility complex class II association and induction of 
T cell responses by carbohydrates and glycopeptides. Springer Semin 
Immunopathol. 1993;15(2–3):293–302.
 18. Harding CV, Kihlberg J, Elofsson M, Magnusson G, Unanue ER. Glycopep‑
tides bind MHC molecules and elicit specific T cell responses. J Immunol. 
1993;151(5):2419–24125.
 19. Avci FY, Li X, Tsuji M, Kasper DL. A mechanism for glycoconjugate vaccine 
activation of the adaptive immune system and its implications for vac‑
cine design. Nat Med. 2011;17(12):1602–9.
 20. Dow JM, Mauri M, Scott TA, Wren BW. Improving protein glycan coupling 
technology (PGCT) for glycoconjugate vaccine production. Expert Rev 
Vaccines. 2020;19(6):507–27.
 21. Kay E, Cuccui J, Wren BW. Recent advances in the production of recombi‑
nant glycoconjugate vaccines. npj Vaccines. 2019;4(1):16.
 22. Szymanski CM, Ruijin Y, Ewing CP, Trust TJ, Guerry P. Evidence for a system 
of general protein glycosylation in Campylobacter jejuni. Mol Microbiol. 
1999;32(5):1022–30.
 23. Parkhill J, Wren BW, Mungall K, Ketley JM, Churcher C, Basham D, et al. The 
genome sequence of the food‑borne pathogen Campylobacter jejuni 
reveals hypervariable sequences. Nature. 2000;403(6770):665–8.
 24. Wacker M, Linton D, Hitchen PG, Nita‑Lazar M, Haslam SM, North SJ, et al. 
N‑linked glycosylation in Campylobacter jejuni and its functional transfer 
into E. coli. Science (80‑). 2002;298(5599):1790–3.
 25. Feldman MF, Wacker M, Hernandez M, Hitchen PG, Marolda CL, Kowarik 
M, et al. Engineering N‑linked protein glycosylation with diverse O anti‑
gen lipopolysaccharide structures in Escherichia coli. Proc Natl Acad Sci U 
S A. 2005;102(8):3016–21.
 26. Kowarik M, Young NM, Numao S, Schulz BL, Hug I, Callewaert N, et al. 
Definition of the bacterial N‑glycosylation site consensus sequence. 
EMBO J. 2006;25(9):1957–66.
 27. Nothaft H, Davis B, Lock YY, Perez‑Munoz ME, Vinogradov E, Walter J, et al. 
Engineering the Campylobacter jejuni N‑glycan to create an effective 
chicken vaccine. Sci Rep. 2016;6:1–12.
 28. Vohra P, Chintoan‑uta C, Terra VS, Bremner A, Cuccui J, Wren BW, et al. 
Evaluation of glycosylated FLPA and SODB as subunit vaccines against 
campylobacter jejuni colonisation in chickens. Vaccines. 2020;8(3):1–14.
 29. Pan C, Sun P, Liu B, Liang H, Peng Z, Dong Y, et al. Biosynthesis of 
conjugate vaccines using an O‑linked glycosylation system. MBio. 
2016;7(2):e00443‑e516.
 30. Sun P, Pan C, Zeng M, Liu B, Liang H, Wang D, et al. Design and production 
of conjugate vaccines against S. Paratyphi A using an O‑linked glycosyla‑
tion system in vivo. npj Vaccines. 2018;3(1):1–9.
 31. Huang J, Pan C, Sun P, Feng E, Wu J, Zhu L, et al. Application of an 
O‑linked glycosylation system in yersinia enterocolitica serotype O:9 to 
generate a new candidate vaccine against brucella abortus. Microorgan‑
isms. 2020;8(3):436.
 32. Iwashkiw JA, Fentabil MA, Faridmoayer A, Mills DC, Peppler M, Czibener 
C, et al. Exploiting the Campylobacter jejuni protein glycosylation system 
for glycoengineering vaccines and diagnostic tools directed against 
brucellosis. Microb Cell Fact. 2012;25:11.
 33. Dziva F, Stevens MP. Colibacillosis in poultry: Unravelling the molecular 
basis of virulence of avian pathogenic Escherichia coli in their natural 
hosts. Vol. 37, Avian Pathology; 2008. p. 355–66.
 34. Nothaft H, Scott NE, Vinogradov E, Liu X, Hu R, Beadle B, et al. Diversity in 
the protein N‑glycosylation pathways within the Campylobacter genus. 
Mol Cell Proteomics. 2012;11(11):1203–19.
 35. Scott NE, Parker BL, Connolly AM, Paulech J, Edwards AVG, Crossett B, 
et al. Simultaneous glycan‑peptide characterization using hydrophilic 
interaction chromatography and parallel fragmentation by CID, higher 
energy collisional dissociation, and electron transfer dissociation MS 
applied to the N‑linked glycoproteome of Campylobact. Mol Cell Prot‑
eomics. 2011;10(2):S1–18.
 36. Abouelhadid S, North SJ, Hitchen P, Vohra P, Chintoan‑Uta C, Stevens 
M, et al. Quantitative analyses reveal novel roles for n‑glycosylation in a 
major enteric bacterial pathogen. MBio. 2019;10(2):1–15.
 37. Cain JA, Dale AL, Niewold P, Klare WP, Man L, White MY, et al. Proteomics 
reveals multiple phenotypes associated with n‑linked glycosylation in 
Campylobacter jejuni. Mol Cell Proteomics. 2019;18(4):715–34.
 38. Abouelhadid S, Raynes J, Bui T, Cuccui J, Wren BW. Characterization of 
posttranslationally modified multidrug efflux pumps reveals an unex‑
pected link between glycosylation and antimicrobial resistance. MBio. 
2020;11(6):1–19.
 39. Alemka A, Nothaft H, Zheng J, Szymanski CM. N‑glycosylation of campy‑
lobacter jejuni surface proteins promotes bacterial fitness. Infect Immun. 
2013;81(5):1674–82.
 40. van Sorge NM, Bleumink NMC, van Vliet SJ, Saeland E, van der Pol WL, van 
Kooyk Y, et al. N‑glycosylated proteins and distinct lipooligosaccharide 
glycoforms of Campylobacter jejuni target the human C‑type lectin 
receptor MGL. Cell Microbiol. 2009;11(12):1768–81.
 41. Nothaft H, Davis B, Lock YY, Perez‑Munoz ME, Vinogradov E, Walter J, et al. 
Engineering the Campylobacter jejuni N‑glycan to create an effective 
chicken vaccine. Sci Rep. 2016;6(1):1–12.
 42. Nothaft H, Perez‑Muñoz ME, Gouveia GJ, Duar RM, Wanford JJ, Lango‑
Scholey L, et al. Coadministration of the Campylobacter jejuni N‑glycan‑
based vaccine with probiotics improves vaccine performance in broiler 
chickens. Appl Environ Microbiol. 2017;83(23):e01523‑17.
 43. Price NL, Goyette‑Desjardins G, Nothaft H, Valguarnera E, Szymanski 
CM, Segura M, et al. Glycoengineered outer membrane vesicles: a novel 
platform for bacterial vaccines. Sci Rep. 2016;22:6.
 44. Wilde S, Jiang Y, Tafoya AM, Horsman J, Yousif M, Vazquez LA, et al. 
Salmonella‑vectored vaccine delivering three Clostridium perfringens 
antigens protects poultry against necrotic enteritis. Wu S‑B, editor. PLoS 
One. 2019 Feb 12;14(2):e0197721.
 45. Dziva F, Hauser H, Connor TR, van Diemen PM, Prescott G, Langridge 
GC, et al. Sequencing and functional annotation of avian pathogenic 
Escherichia coli serogroup O78 strains reveal the evolution of E. coli 
lineages pathogenic for poultry via distinct mechanisms. Infect Immun. 
2013;81(3):838–49.
 46. Linton D, Dorrell N, Hitchen PG, Amber S, Karlyshev AV, Morris HR, et al. 
Functional analysis of the Campylobacter jejuni N‑linked protein glyco‑
sylation pathway. Mol Microbiol. 2005;55(6):1695–703.
 47. Yates LE, Natarajan A, Li M, Hale ME, Mills DC, DeLisa MP. Glyco‑recoded 
Escherichia coli: Recombineering‑based genome editing of native poly‑
saccharide biosynthesis gene clusters. Metab Eng. 2019;1(53):59–68.
 48. Englaender JA, Jones JA, Cress BF, Kuhlman TE, Linhardt RJ, Koffas 
MAG. Effect of genomic integration location on heterologous pro‑
tein expression and metabolic engineering in E. coli. ACS Synth Biol. 
2017;6(4):710–20.
 49. Donnenberg MS, Kaper JB. Construction of an eae deletion mutant of 
enteropathogenic Escherichia coli by using a positive‑selection suicide 
vector. Infect Immun. 1991;59(12):4310–7.
 50. Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA, Smith HO. 
Enzymatic assembly of DNA molecules up to several hundred kilobases. 
Nat Methods. 2009;6(5):343–5.
 51. Johnson JR, Lockman HA, Owens K, Jelacic S, Tarr PI. High‑frequency 
secondary mutations after suicide‑driven allelic exchange mutagen‑
esis in extraintestinal pathogenic Escherichia coli. J Bacteriol. 
2003;185(17):5301–5.
 52. Young NM, Brisson JR, Kelly J, Watson DC, Tessier L, Lanthier PH, et al. 
Structure of the N‑linked glycan present on multiple glycoproteins 
in the gram‑negative bacterium, Campylobacter jejuni. J Biol Chem. 
2002;277(45):42530–9.
 53. Alaimo C, Catrein I, Morf L, Marolda CL, Callewaert N, Valvano MA, et al. 
Two distinct but interchangeable mechanisms for flipping of lipid‑linked 
oligosaccharides. EMBO J. 2006;25(5):967–76.
 54. Heinrichs DE, Yethon JA, Whitfield C. Molecular basis for structural diver‑
sity in the core regions of the lipopolysaccharides of Escherichia coli and 
Salmonella enterica. Mol Microbiol. 1998;30(2):221–32.
 55. Cuccui J, Thomas RM, Moule MG, D’Elia RV, Laws TR, Mills DC, et al. 
Exploitation of bacterial N‑linked glycosylation to develop a novel recom‑
binant glycoconjugate vaccine against Francisella tularensis. Open Biol. 
2013;3(5):130002.
Page 26 of 26Mauri et al. Microb Cell Fact          (2021) 20:193 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 56. Marshall LE, Nelson M, Davies CH, Whelan AO, Jenner DC, Moule MG, 
et al. An O‑Antigen glycoconjugate vaccine produced using protein 
glycan coupling technology is protective in an inhalational rat model of 
tularemia. J Immunol Res. 2018;29(2018):1–12.
 57. Garcia‑Quintanilla F, Iwashkiw JA, Price NL, Stratilo C, Feldman MF. 
Production of a recombinant vaccine candidate against Burkholderia 
pseudomallei exploiting the bacterial N‑glycosylation machinery. Front 
Microbiol. 2014;5(JULY):381.
 58. Poulvac E. coli Home | Zoetis US. [cited 2021 May 7]. https:// www. zoeti 
sus. com/ produ cts/ poult ry/ poulv ac‑e_ coli/ defau lt. aspx.
 59. Keyburn AL, Boyce JD, Vaz P, Bannam TL, Ford ME, Parker D, et al. NetB, 
a new toxin that is associated with avian necrotic enteritis caused by 
Clostridium perfringens. PLoS Pathog. 2008;4(2):e26.
 60. Timbermont L, Haesebrouck F, Ducatelle R, Van Immerseel F. Necrotic 
enteritis in broilers: An updated review on the pathogenesis. Vol. 40, 
Avian Pathology. Avian Pathol; 2011. p. 341–7.
 61. Savva CG, Da Costa SPF, Bokori‑Brown M, Naylor CE, Cole AR, Moss DS, 
et al. Molecular architecture and functional analysis of NetB, a pore‑form‑
ing toxin from Clostridium perfringens. J Biol Chem. 2013;288(5):3512–22.
 62. Dykxhoorn DM, St. Pierre R, Linn T. A set of compatible tac promoter 
expression vectors. Gene. 1996;177(1–2):133–6.
 63. Valdivia RH, Falkow S. Bacterial genetics by flow cytometry: Rapid isola‑
tion of Salmonella typhimurium acid‑inducible promoters by differential 
fluorescence induction. Mol Microbiol. 1996;22(2):367–78.
 64. Alber A, Morris KM, Bryson KJ, Sutton KM, Monson MS, Chintoan‑Uta C, 
et al. Avian Pathogenic Escherichia coli (APEC) strain‑dependent immu‑
nomodulation of respiratory granulocytes and mononuclear phagocytes 
in CSF1R‑reporter transgenic chickens. Front Immunol. 2020;10:10.
 65. Balic A, Chintoan‑Uta C, Vohra P, Sutton KM, Cassady‑Cain RL, Hu T, et al. 
Antigen sampling csf1r‑expressing epithelial cells are the functional 
equivalents of mammalian m cells in the avian follicle‑associated epithe‑
lium. Front Immunol. 2019;10:2495.
 66. Mellata M, Touchman JW, Curtis R. Full sequence and comparative analy‑
sis of the plasmid pAPEC‑1 of avian pathogenic E. coli χ7122 (O78:k80:H9). 
PLoS ONE. 2009;4(1):e4232.
 67. Mellata M, Maddux JT, Nam T, Thomson N, Hauser H, Stevens MP, et al. 
New insights into the bacterial fitness‑associated mechanisms revealed 
by the characterization of large plasmids of an avian pathogenic E. coli. 
Ravel J, editor. PLoS One. 2012;7(1):e29481.
 68. McEwen SA, Collignon PJ. Antimicrobial resistance: a one health perspec‑
tive. In: Antimicrobial resistance in bacteria from livestock and compan‑
ion animals. American Society of Microbiology; 2018. p. 521–47.
 69. Micoli F, Bagnoli F, Rappuoli R, Serruto D. The role of vaccines in combat‑
ting antimicrobial resistance. Vol. 19, Nature reviews microbiology. Nature 
research; 2021. p. 287–302.
 70. Meeusen ENT, Walker J, Peters A, Pastoret PP, Jungersen G. Current status 
of veterinary vaccines. Vol. 20, Clinical microbiology reviews. American 
Society for Microbiology (ASM); 2007. p. 489–510.
 71. Siegrist C‑A. Vaccine immunology. 2005 [cited 2021 May 9]. https:// www. 
who. int/ immun izati on/ docum ents/ Elsev ier_ Vacci ne_ immun ology. pdf.
 72. Pumtang‑On P, Mahony TJ, Hill RA, Vanniasinkam T. A systematic review of 
campylobacter jejuni vaccine candidates for chickens. Vol. 9, Microorgan‑
isms. MDPI AG; 2021. p. 1–48.
 73. Elmi A, Nasher F, Dorrell N, Wren B, Gundogdu O. Revisiting Campy‑
lobacter jejuni virulence and fitness factors: role in sensing, adapting, 
and competing. Vol. 10, Frontiers in cellular and infection microbiology. 
Frontiers Media S.A.; 2021.
 74. Li H, Debowski AW, Liao T, Tang H, Nilsson HO, Marshall BJ, et al. Under‑
standing protein glycosylation pathways in bacteria. Vol. 12, Future 
microbiology. Future Medicine Ltd.; 2017. p. 59–72.
 75. Jann B, Reske K, Jann K. Heterogeneity of lipopolysaccharides. Analysis of 
polysaccharide chain lengths by sodium dodecylsulfate‑polyacrylamide 
gel electrophoresis. Eur J Biochem. 1975;60(1):239–46.
 76. Davison J. Towards safer vectors for the field release of recombinant 
bacteria. Vol. 1, Environmental biosafety research. 2002. p. 9–18.
 77. Kong W, Wanda SY, Zhang X, Bollen W, Tinge SA, Roland KL, et al. Regu‑
lated programmed lysis of recombinant Salmonella in host tissues to 
release protective antigens and confer biological containment. Proc Natl 
Acad Sci U S A. 2008;105(27):9361–6.
 78. Ferrières L, Hémery G, Nham T, Guérout AM, Mazel D, Beloin C, et al. Silent 
mischief: Bacteriophage Mu insertions contaminate products of Escheri-
chia coli random mutagenesis performed using suicidal transposon deliv‑
ery plasmids mobilized by broad‑host‑range RP4 conjugative machinery. 
J Bacteriol. 2010;192(24):6418–27.
 79. Liu D, Reeves PR. Escherichia coli K12 regains its O antigen. Microbiology. 
1994;140(1):49–57.
 80. Datsenko KA, Wanner BL. One‑step inactivation of chromosomal genes 
in Escherichia coli K‑12 using PCR products. Proc Natl Acad Sci U S A. 
2000;97(12):6640–5.
 81. Enggist E, Schneider MJ, Schulz H, Thöny‑Meyer L. Biochemical and muta‑
tional characterization of the heme chaperone CcmE reveals a heme 
binding site. J Bacteriol. 2003;185(1):175–83.
 82. Wacker M, Wang L, Kowarik M, Dowd M, Lipowsky G, Faridmoayer A, et al. 
Prevention of staphylococcus aureus infections by glycoprotein vaccines 
synthesized in escherichia coli. J Infect Dis. 2014;209(10):1551–61.
 83. Martin M. Cutadapt removes adapter sequences from high‑throughput 
sequencing reads. EMBnet J. 2011;17(1):10.
 84. GitHub—najoshi/sickle: Windowed adaptive trimming for fastq files 
using quality. 2011 [cited 2021 Apr 27]. https:// github. com/ najos hi/ sickle.
 85. Li H, Durbin R. Fast and accurate long‑read alignment with Burrows‑
Wheeler transform. Bioinformatics. 2010;26(5):589–95.
 86. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The 
sequence alignment/map format and SAMtools. Bioinformatics. 
2009;25(16):2078–9.
 87. Using seqtk to trim and process reads at an insanely high speed— angus 
5.0 documentation. 2013 [cited 2021 May 9]. https:// angus. readt hedocs. 
io/ en/ 2013/ seqtk_ tools. html.
 88. Liao Y, Smyth GK, Shi W. FeatureCounts: an efficient general purpose 
program for assigning sequence reads to genomic features. Bioinformat‑
ics. 2014;30(7):923–30.
 89. Love MI, Huber W, Anders S. Moderated estimation of fold change and 
dispersion for RNA‑seq data with DESeq2. Genome Biol. 2014;15(12):550.
 90. Park S, Reyer MA, Mclean EL, Liu W, Fei J. An improved method for bacte‑
rial immunofluorescence staining to eliminate antibody exclusion from 
the fixed nucleoid. Biochemistry. 2019;58(45):4457–65.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
